

FIG. 7. FKBP8 interacts with NS5A in the membranous web. (A) The Huh-7 9-13 replicon cells were stained with specific antibodies to FKBP8 and NS5A as described in Fig. 6A. Identical fields were observed under EM by using the correlative FM-EM technique. Arrows indicate the areas NS5A and FKBP8 are colocalizing. Right panels indicate the magnified images of the small black boxes. Highly electron-dense and folded membranous structures were observed by a highly magnified EM. (B) Control cells in which the replicon cells were cured by IFN- $\alpha$  treatment were processed in the same procedures. No electron-dense structure was observed in the cytoplasm.

the correlative FM-EM technique described above. This method allowed us to examine the colocalization of the molecules by both FM and EM in the same samples, yielding two different but complementary data sets. The replicon cells were stained with antibodies to FKBP8 and NS5A and examined under FM (Fig. 7A, left panels), and the same fields were observed under EM (Fig. 7A, right panels). The compartments colocalizing FKBP8 and NS5A (arrows) exhibited a high electron density and a folded membranous structure that was similar to a membranous web (15, 32). In contrast, the replicon cells cured by IFN- $\alpha$  treatment did not have the electron-dense structure (Fig. 7B). These results suggest that FKBP8 interacts with NS5A on the membranous web in cells replicating HCV RNA.

#### DISCUSSION

HCV NS5A is a multifunctional protein involved in viral replication and pathogenesis (29). In a previous study, we have shown that NS5A specifically interacts with FKBP8 and recruits Hsp90 to the viral RNA replication complex through the interaction of the carboxylate clump structure of FKBP8 with the C-terminal MEEVD motif of Hsp90 (37). Although we demonstrated that a TPR domain other than the carboxylate clump region of FKBP8 was responsible for the specific interaction with NS5A (37), the precise binding amino acid residue of the interaction was not determined. In the present study, FKBP8 exhibited a specific interaction with the immobilized

NS5A in a dose-dependent manner with an equilibrium dissociation constant ( $K_d$ ) of 82 nM as determined by the SPR, but no interaction with FKBP52 was detected. Furthermore, mutational analysis suggested that Val or Ile at the amino acid residue 121 of NS5A was responsible for the specific interaction with FKBP8. The subgenomic HCV replicon RNA harboring the mutation of Val<sup>121</sup> to Ala within NS5A leads to severe impairment of RNA replication, and reversion from Ala<sup>121</sup> to Val was detected, suggesting that interaction of FKBP8 with NS5A through the Val<sup>121</sup> is crucial for HCV replication. The crystal structure of NS5A domain 1 revealed that Val<sup>121</sup> is located on one of the  $\beta$ -sheet structures in the 1B subdomain and the side chain of the residue is located within the hydrophobic core (46); therefore, the Val<sup>121</sup> may be involved in the maintenance of the  $\beta$ -sheet structure in the subdomain rather than the direct interaction with FKBP8. However, it remains feasible to speculate that unidentified host factors may be involved in the conformational change of region, including Val<sup>121</sup> for direct interaction with FKBP8. Further studies, including a structural analysis of FKBP8, are needed to clarify the mechanisms by which HCV is replicated through the interaction of NS5A, FKBP8, and Hsp90.

The current combination therapy with pegylated IFN- $\alpha$  and ribavirin achieves a sustained virological response in half of the patients infected with a high viral load of HCV of genotype 1b (30). However, it is difficult to achieve the complete removal of viruses by antiviral drugs targeted to the viral enzymes, includ-

ing proteases and polymerases, from patients persistently infected with RNA viruses that exhibit a quasispecies nature, such as human immunodeficiency virus and HCV. Viral quasispecies are not a simple collection of diverse mutants but a group of interactive variants capable of adapting to new environments (48). Cyclosporine treatment has been shown to be effective for patients infected with HCV of genotype 1b (20) and suppresses HCV RNA replication *in vitro* (52). In addition, cyclosporine has been shown to disrupt the interaction between NS5B and cyclophilin B, which is required for an efficient RNA-binding of NS5B (53). Cyclophilins and FKBP8 are classified as immunophilins capable of binding to the immunosuppressants cyclosporine and FK506, respectively (26). The family members do not share a homologous domain other than drug-binding and enzymatically active domains, based on their amino acid sequences, substrate specificities, and inhibitor sensitivities. However, cyclosporine-resistant RNA replicon was shown to exhibit mutations not only in NS5B but also in NS5A (12, 41), suggesting that cyclosporine might affect the viral replication through the nucleotide-binding ability of NS5B, as well as the function of NS5A. Recently, geldanamycin, an inhibitor of Hsp90, was shown to drastically impair the replication of poliovirus without any emergence of escape mutants (14). Therefore, the elucidation of host proteins, including immunophilins and chaperones, participating in the HCV replication complex may lead to the development of new therapeutics for chronic hepatitis C with a broad spectrum and a low possibility of emergence of revertant viruses. In particular, disruption of the specific interaction of Val<sup>121</sup> of NS5A with the TPR domain of FKBP8 might be an ideal target for a novel therapeutic measure.

Egger et al. reported that NS4B alters the intracellular membrane to form a membranous web structure consisting of a membrane-associated multiprotein complex localized in the cytoplasmic compartments distinct from the mitochondria *in vitro* and in the liver of an HCV-infected chimpanzee, suggesting that the membranous web forms the viral replication complex (8). An N-terminal amphipathic helix of NS4B plays an important role in the viral replication, as well as in the correct localization of other NS proteins including NS5A (9). Furthermore, VAP-B was reported to interact with Nir2 protein through the FFAT (named for two phenylalanines [i.e., FF] in the acidic tract) motif and to remodel the ER structure to form a convoluted membrane structure resembling a membranous web (3). In addition, VAP-A and B interact with not only NS5A but also NS5B (13, 16, 47), suggesting that the complex of NS5A with FKBP8 might be recruited on the membranous web by NS4B and/or VAPs and participate in the HCV replication.

FKBP8 has been shown to be localized mainly on the mitochondria and to interact with Bcl-2 to sequester Bcl-2 on the mitochondria (7, 44). However, HCV RNA was suggested to be replicated in the membranous web structure in replicon cells (8, 13, 15), and NS5A was reported to localize on the ER, Golgi apparatus (2, 6, 16), and lipid droplets (43). Figures 6C and 7A clearly indicate that the intracellular compartment including NS5A and FKBP8 is distinct from mitochondria. The HCV core protein was shown to upregulate genes related to fatty acid biosynthesis through the interaction with proteasome activator PA28 $\gamma$ /REG $\gamma$  in the nucleus (34) and to induce ac-

cumulation of cytoplasmic lipid droplets in the mouse liver (35). Recently, it was shown that the HCV core protein of the genotype 2a JFH1 strain recruits the replication complex to the lipid droplet-associated membranes, and HCV particles were detected in close proximity to the lipid droplets, suggesting that lipid droplets induced by core protein participate in the assembly of HCV particles (31). In addition, the lipid droplets including the core protein were surrounded by the nonstructural proteins was also detected in cells expressing the chimeric HCV genomes encoding core to a part of NS2 proteins of genotype 1b or 1a strain and the nonstructural proteins of JFH1 strain (31). In the present study, FKBP8 was shown to be colocalized with NS5A in a highly electron-dense intracellular compartment indistinguishable from the membranous web. Although the total amount of FKBP8 was not changed by the treatment of the replicon cells by IFN- $\alpha$  (data not shown), the membranous web structure where FKBP8 and NS5A had accumulated was removed by the treatment (Fig. 7B). These results suggest that the replication of the subgenomic HCV RNA induces the formation of a membranous web structure in which NS5A and FKBP8 are colocalized but has no effect on the expression level of FKBP8. Furthermore, we could not detect any colocalization of FKBP8 and NS5A with the lipid droplets in the replicon cells harboring a full-length genome of the genotype 1b Con1 strain (data not shown). Although the relationships between the membranous web and lipid droplets remain unknown, these discrepancies might be attributable to the difference in HCV genotypes of the nonstructural proteins that consist of the major components of the replication complex determining the efficiency of HCV replication.

In conclusion, our data indicate that NS5A directly binds to FKBP8 through the Val<sup>121</sup> and colocalizes in the convoluted membrane structure known as the membranous web. Future studies on the role of FKBP8 in the replication of HCV might contribute to the development of a new type of anti-HCV drugs with a low frequency of emergence of drug-resistant breakthrough viruses.

#### ACKNOWLEDGMENTS

We thank H. Murase for secretarial work. We also thank R. Bartenschlager and C. E. Cameron for providing the plasmids. We are grateful to the staff of the Center for Research and Education for their help in using the Biacore 2000.

This work was supported in part by grants-in-aid from the Ministry of Health, Labor, and Welfare; the Ministry of Education, Culture, Sports, Science, and Technology; the 21st Century Center of Excellence Program; and the Foundation for Biomedical Research and Innovation.

#### REFERENCES

1. Abe, T., Y. Kaname, I. Hamamoto, Y. Tsuda, X. Wen, S. Taguwa, K. Morishii, O. Takeuchi, T. Kawai, T. Kanto, N. Hayashi, S. Akira, and Y. Matsuura. 2007. Hepatitis C virus nonstructural protein 5A modulates the Toll-like receptor-MyD88-dependent signaling pathway in macrophage cell lines. *J. Virol.* 81:8953–8966.
2. Aizaki, H., K. S. Choi, M. Liu, Y. J. Li, and M. M. Lai. 2006. Polypyrimidine-tract-binding protein is a component of the HCV RNA replication complex and necessary for RNA synthesis. *J. Biomed. Sci.* 13:469–480.
3. Amarilio, R., S. Ramachandran, H. Sabanay, and S. Lev. 2005. Differential regulation of endoplasmic reticulum structure through VAP-Nir protein interaction. *J. Biol. Chem.* 280:5934–5944.
4. Appel, N., T. Pietschmann, and R. Bartenschlager. 2005. Mutational analysis of hepatitis C virus nonstructural protein 5A: potential role of differential phosphorylation in RNA replication and identification of a genetically flexible domain. *J. Virol.* 79:3187–3194.

5. Boulant, S., P. Targett-Adams, and J. McLauchlan. 2007. Disrupting the association of hepatitis C virus core protein with lipid droplets correlates with a loss in production of infectious virus. *J. Gen. Virol.* 88:2204–2213.
6. Brass, V., E. Bieck, R. Montserret, B. Wolk, J. A. Hellings, H. E. Blum, F. Penin, and D. Moradpour. 2002. An amino-terminal amphipathic alpha-helix mediates membrane association of the hepatitis C virus nonstructural protein 5A. *J. Biol. Chem.* 277:8130–8139.
7. Bulgakov, O. V., J. T. Eggenschwiler, D. H. Hong, K. V. Anderson, and T. Li. 2004. FKBP8 is a negative regulator of mouse sonic hedgehog signaling in neural tissues. *Development* 131:2149–2159.
8. Egger, D., B. Wolk, R. Gosert, L. Bianchi, H. E. Blum, D. Moradpour, and K. Bienz. 2002. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. *J. Virol.* 76:5974–5984.
9. Elazar, M., K. H. Cheong, P. Liu, H. B. Greenberg, C. M. Rice, and J. S. Glenn. 2003. Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication. *J. Virol.* 77:6055–6061.
10. Enomoto, N., I. Sakuma, Y. Asahina, M. Kurosaki, T. Murakami, C. Yamamoto, N. Izumi, F. Marumo, and C. Sato. 1995. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. *J. Clin. Invest.* 96:224–230.
11. Evans, M. J., C. M. Rice, and S. P. Goff. 2004. Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication. *Proc. Natl. Acad. Sci. USA* 101:13038–13043.
12. Fernandes, F., D. S. Poole, S. Hoover, R. Middleton, A. C. Andrei, J. Gerstner, and R. Striker. 2007. Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B. *Hepatology* 46:1026–1033.
13. Gao, L., H. Aizaki, J. W. He, and M. M. Lai. 2004. Interactions between viral nonstructural proteins and host protein hVAP-33 mediate the formation of hepatitis C virus RNA replication complex on lipid raft. *J. Virol.* 78:3480–3488.
14. Geller, R., M. Vignuzzi, R. Andino, and J. Frydman. 2007. Evolutionary restraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance. *Genes Dev.* 21:195–205.
15. Gosert, R., D. Egger, V. Lohmann, R. Bartenschlager, H. E. Blum, K. Bienz, and D. Moradpour. 2003. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. *J. Virol.* 77:5487–5492.
16. Hamamoto, I., Y. Nishimura, T. Okamoto, H. Aizaki, M. Liu, Y. Mori, T. Abe, T. Suzuki, M. M. Lai, T. Miyamura, K. Moriishi, and Y. Matsuura. 2005. Human VAP-B is involved in hepatitis C virus replication through interaction with NS5A and NS5B. *J. Virol.* 79:13473–13482.
17. Ho, S. N., H. D. Hunt, R. M. Horton, J. K. Pullen, and L. R. Pease. 1989. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. *Gene* 77:51–59.
18. Horton, R. M., H. D. Hunt, S. N. Ho, J. K. Pullen, and L. R. Pease. 1989. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. *Gene* 77:61–68.
19. Huang, L., E. V. Sineva, M. R. Hargittai, S. D. Sharma, M. Suthar, K. D. Raney, and C. E. Cameron. 2004. Purification and characterization of hepatitis C virus nonstructural protein 5A expressed in *Escherichia coli*. *Protein. Expr. Purif.* 37:144–153.
20. Inoue, K., K. Sekiyama, M. Yamada, T. Watanabe, H. Yasuda, and M. Yoshida. 2003. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. *J. Gastroenterol.* 38:567–572.
21. Kanda, T., A. Basu, R. Steele, T. Wakita, J. S. Ryerse, R. Ray, and R. B. Ray. 2006. Generation of infectious hepatitis C virus in immortalized human hepatocytes. *J. Virol.* 80:4633–4639.
22. Kapadia, S. B., and F. V. Chisari. 2005. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. *Proc. Natl. Acad. Sci. USA* 102:2561–2566.
23. Krieger, N., V. Lohmann, and R. Bartenschlager. 2001. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. *J. Virol.* 75:4614–4624.
24. Lamarre, D., P. C. Anderson, M. Bailey, P. Beaulieu, G. Bolger, P. Bonneau, M. Bos, D. R. Cameron, M. Cartier, M. G. Cordingley, A. M. Faucher, N. Goudreau, S. H. Kawai, G. Kukolj, L. Lagace, S. R. LaPlante, H. Narjes, M. A. Poupard, J. Rancourt, R. E. Sentjens, R. St. George, B. Simoneau, G. Steinmann, D. Thibeault, Y. S. Tsantrizos, S. M. Weldon, C. L. Yong, and M. Llinas-Brunet. 2003. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. *Nature* 426:186–189.
25. Lindenbach, B. D., M. J. Evans, A. J. Syder, B. Wolk, T. L. Tellinghuisen, C. C. Liu, T. Maruyama, R. O. Hynes, D. R. Burton, J. A. McKeating, and C. M. Rice. 2005. Complete replication of hepatitis C virus in cell culture. *Science* 309:623–626.
26. Liu, J., J. D. Farmer, Jr., W. S. Lane, J. Friedman, I. Weissman, and S. L. Schreiber. 1991. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. *Cell* 66:807–815.
27. Lohmann, V., F. Korner, J. Koch, U. Herian, L. Theilmann, and R. Bartenschlager. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. *Science* 285:110–113.
28. Macdonald, A., K. Crowder, A. Street, C. McCormick, and M. Harris. 2004. The hepatitis C virus NS5A protein binds to members of the Src family of tyrosine kinases and regulates kinase activity. *J. Gen. Virol.* 85:721–729.
29. Macdonald, A., and M. Harris. 2004. Hepatitis C virus NS5A: tales of a promiscuous protein. *J. Gen. Virol.* 85:2485–2502.
30. Manns, M. P., J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, Z. D. Goodman, K. Koury, M. Ling, and J. K. Albrecht. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 358:958–965.
31. Miyazari, Y., K. Atsuzawa, N. Usuda, K. Watashi, T. Hishiki, M. Zayas, R. Bartenschlager, T. Wakita, M. Hijikata, and K. Shimotohno. 2007. The lipid droplet is an important organelle for hepatitis C virus production. *Nat. Cell Biol.* 9:1089–1097.
32. Moradpour, D., F. Penin, and C. M. Rice. 2007. Replication of hepatitis C virus. *Nat. Rev. Microbiol.* 5:453–463.
33. Moriishi, K., and Y. Matsuura. 2003. Mechanisms of hepatitis C virus infection. *Antivir. Chem. Chemother.* 14:285–297.
34. Moriishi, K., R. Mochizuki, K. Moriya, H. Miyamoto, Y. Mori, T. Abe, S. Murata, K. Tanaka, T. Miyamura, T. Suzuki, K. Koike, and Y. Matsuura. 2007. Critical role of PA28gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. *Proc. Natl. Acad. Sci. USA* 104:1661–1666.
35. Moriya, K., H. Yotsuyanagi, Y. Shintani, H. Fujie, K. Ishibashi, Y. Matsuura, T. Miyamura, and K. Koike. 1997. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. *J. Gen. Virol.* 78(Pt. 7):1527–1531.
36. Niwa, H., K. Yamamura, and J. Miyazaki. 1991. Efficient selection for high-expression transfectants with a novel eukaryotic vector. *Gene* 108:193–199.
37. Okamoto, T., Y. Nishimura, T. Ichimura, K. Suzuki, T. Miyamura, T. Suzuki, K. Moriishi, and Y. Matsuura. 2006. Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90. *EMBO J.* 25:5015–5025.
38. Pawlotsky, J. M., and G. Germanidis. 1999. The nonstructural 5A protein of hepatitis C virus. *J. Viral Hepat.* 6:343–356.
39. Randall, G., M. Panis, J. D. Cooper, T. L. Tellinghuisen, K. E. Sukhodolets, S. Pfeffer, M. Landthaler, P. Landgraf, S. Kan, B. D. Lindenbach, M. Chien, D. B. Weir, J. J. Russo, J. Ju, M. J. Brownstein, R. Sheridan, C. Sander, M. Zavolan, T. Tuschl, and C. M. Rice. 2007. Cellular cofactors affecting hepatitis C virus infection and replication. *Proc. Natl. Acad. Sci. USA* 104:12884–12889.
40. Rieder, C. L., and S. S. Bowser. 1985. Correlative immunofluorescence and electron microscopy on the same section of Epon-embedded material. *J. Histochem. Cytochem.* 33:165–171.
41. Robida, J. M., H. B. Nelson, Z. Liu, and H. Tang. 2007. Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro. *J. Virol.* 81:5829–5840.
42. Sakamoto, H., K. Okamoto, M. Aoki, H. Kato, A. Katsume, A. Ohta, T. Tsukuda, N. Shimma, Y. Aoki, M. Arisawa, M. Kohara, and M. Sudoh. 2005. Host sphingolipid biosynthesis as a target for hepatitis C virus therapy. *Nat. Chem. Biol.* 1:333–337.
43. Shi, S. T., S. J. Polyak, H. Tu, D. R. Taylor, D. R. Gretch, and M. M. Lai. 2002. Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. *Virology* 292:198–210.
44. Shirane, M., and K. I. Nakayama. 2003. Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to mitochondria and inhibits apoptosis. *Nat. Cell Biol.* 5:28–37.
45. Tellinghuisen, T. L., J. Marcotrigiano, A. E. Gorbalenya, and C. M. Rice. 2004. The NS5A protein of hepatitis C virus is a zinc metalloprotein. *J. Biol. Chem.* 279:48576–48587.
46. Tellinghuisen, T. L., J. Marcotrigiano, and C. M. Rice. 2005. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. *Nature* 435:374–379.
47. Tu, H., L. Gao, S. T. Shi, D. R. Taylor, T. Yang, A. K. Mircheff, Y. Wen, A. E. Gorbalenya, S. B. Hwang, and M. M. Lai. 1999. Hepatitis C virus RNA polymerase and NS5A complex with a SNARE-like protein. *Virology* 263:30–41.
48. Vignuzzi, M., J. K. Stone, J. J. Arnold, C. E. Cameron, and R. Andino. 2006. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. *Nature* 439:344–348.
49. Wakita, T., T. Pietschmann, T. Kato, T. Date, M. Miyamoto, Z. Zhao, K. Murthy, A. Habermann, H. G. Krausslich, M. Mizokami, R. Bartenschlager, and T. J. Liang. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. *Nat. Med.* 11:791–796.
50. Wang, C., M. Gale, Jr., B. C. Keller, H. Huang, M. S. Brown, J. L. Goldstein, and J. Ye. 2005. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. *Mol. Cell* 18:425–434.
51. Wasley, A., and M. J. Alter. 2000. Epidemiology of hepatitis C: geographic differences and temporal trends. *Semin. Liver Dis.* 20:1–16.
52. Watashi, K., M. Hijikata, M. Hosaka, M. Yamaji, and K. Shimotohno. 2003.

- Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. *Hepatology* 38:1282–1288.
53. Watashi, K., N. Ishii, M. Hijikata, D. Inoue, T. Murata, Y. Miyanari, and K. Shimotohno. 2005. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. *Mol. Cell* 19:111–122.
54. Ye, J., C. Wang, R. Sumpter, Jr., M. S. Brown, J. L. Goldstein, and M. Gale, Jr. 2003. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. *Proc. Natl. Acad. Sci. USA* 100:15865–15870.
55. Yi, M., and S. M. Lemon. 2004. Adaptive mutations producing efficient replication of genotype 1a hepatitis C virus RNA in normal Huh7 cells. *J. Virol.* 78:7904–7915.
56. Yi, M., R. A. Villanueva, D. L. Thomas, T. Wakita, and S. M. Lemon. 2006. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. *Proc. Natl. Acad. Sci. USA* 103:2310–2315.
57. Zhong, J., P. Gastaminza, G. Cheng, S. Kapadia, T. Kato, D. R. Burton, S. F. Wieland, S. L. Uprichard, T. Wakita, and F. V. Chisari. 2005. Robust hepatitis C virus infection in vitro. *Proc. Natl. Acad. Sci. USA* 102:9294–9299.

# Anti-hepatitis C Virus Activity of Tamoxifen Reveals the Functional Association of Estrogen Receptor with Viral RNA Polymerase NS5B\*

Received for publication, May 30, 2007, and in revised form, August 15, 2007. Published, JBC Papers in Press, August 17, 2007, DOI 10.1074/jbc.M704418200

Koichi Watashi, Daisuke Inoue, Makoto Hijikata, Kaku Goto, Hussein H. Aly, and Kunitada Shimotohno<sup>1</sup>

From the Department of Viral Oncology, Institute for Virus Research, Kyoto University, 53 Kawaharacho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan

Hepatitis C virus (HCV) is a major causative agent of hepatocellular carcinoma. HCV genome replication occurs in the replication complex (RC) around the endoplasmic reticulum membrane. However, the mechanisms regulating the HCV RC remain widely unknown. Here, we used a chemical biology approach to show that estrogen receptor (ESR) is functionally associated with HCV replication. We found that tamoxifen suppressed HCV genome replication. Part of ESR $\alpha$  resided on the endoplasmic reticulum membranes and interacted with HCV RNA polymerase NS5B. RNA interference-mediated knockdown of endogenous ESR $\alpha$  reduced HCV replication. Mechanistic analysis suggested that ESR $\alpha$  promoted NS5B association with the RC and that tamoxifen abrogated NS5B-RC association. Thus, ESR $\alpha$  regulated the presence of NS5B in the RC and stimulated HCV replication. Moreover, the ability of ESR $\alpha$  to regulate NS5B was suggested to serve as a potential novel target for anti-HCV therapeutics.

Estrogen receptor (ESR)<sup>2</sup> belongs to the steroid hormone receptor family of the nuclear receptor superfamily (1). ESR consists of two subtypes, ESR $\alpha$  and ESR $\beta$ . As a primary physiological function, ESR is involved in the transcription for downstream genes in response to stimulation by the ligand, estradiol. In the normal state, ESR is mainly located in the cytoplasm and nucleus. Upon binding of the ligand, ESR dimerizes and translocates into the nucleus, where it binds to the ESR-responsive

elements (ERE) in the DNA promoter of downstream genes and drives transcription. In addition to this classical genomic action, a portion of ESR is located on the membrane, such as the plasma membrane, and involved in the nongenomic function of triggering signal transduction pathways, such as mitogen-activated protein kinase, phosphatidylinositol 3-kinase, and protein kinase C (2–4). Although the molecular basis of ESR membrane retention is not fully understood, one mechanism involves a membrane protein, caveolin (CAV); ESR $\alpha$  interacted with CAV, and this interaction facilitated ESR $\alpha$  localization to the membrane (5, 6). It was also reported that ESR $\alpha$  localizes to the lipid rafts on the plasma membrane (7). The lipid rafts are microdomains of the membrane that form platforms enriched in cholesterol and glycosphingolipids. However, the characteristics and relevance of membrane-associated ESR have not been fully disclosed. Here, we report the novel role of ESR $\alpha$  in the regulation of viral replication.

Hepatitis C virus (HCV), a causative agent of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma, constitutes a serious health problem worldwide (8). HCV has a positive strand RNA genome that produces at least 10 functional viral proteins: core, envelope 1, envelope 2, p7, nonstructural protein 2 (NS2), NS3, NS4A, NS4B, NS5A, and NS5B (9, 10). NS5B is an RNA-dependent RNA polymerase, which plays a central role in viral genome replication (11, 12). HCV genome replication can be evaluated using a HCV subgenomic replicon system, which Lohmann *et al.* (13) first established. In this system, cells carry an HCV subgenome RNA encoding NS3 to NS5B. Using this system, it has been proposed that HCV genome replication occurs in the replication complex (RC), which contains the viral genome RNA and HCV NS proteins. The RC forms on the surface of the intracellular membranes, including the endoplasmic reticulum (ER) membrane, and is surrounded by a membrane structure (14–17). It also has been reported that HCV genome replication associates with the lipid rafts on these intracellular membranes, such as the ER membrane (14, 18). These lipid rafts accumulate CAV2, and HCV proteins involved in viral genome replication cofractionate with CAV2 (18). However, it is largely unknown how the RC is formed and under what mechanism the HCV proteins participate in the RC.

A chemical biology approach is a useful method to analyze the molecular mechanism of viral life cycles as well as cellular physiological processes (19). We employed forward chemical genetics in which we analyzed HCV replication activity as a phenotypic indicator of a cell-based assay to screen chemical

\* This work was supported by grants-in-aid for cancer research and for the second term comprehensive 10-year strategies for cancer control from the Ministry of Health, Labor, and Welfare; by grants-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science, and Technology; by grants-in-aid for the Research for the Future Program from the Japanese Society for the Promotion of Science; and by grants-in-aid for the Program for Promotion of Fundamental Studies in Health Science from the Organization for Pharmaceutical Safety. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> To whom correspondence should be addressed: Dept. of Viral Oncology, Institute for Virus Research, Kyoto University, 53 Kawaharacho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan. Tel.: 81-75-751-4000; Fax: 81-75-751-3998; E-mail: kshimoto@virus.kyoto-u.ac.jp.

<sup>2</sup> The abbreviations used are: ESR, estrogen receptor; HCV, hepatitis C virus; RC, replication complex; ER, endoplasmic reticulum; TAM, tamoxifen; ERE, ESR-responsive element(s); CAV, caveolin; NS, nonstructural protein; MM, microsomal membrane; siRNA, small interfering RNA; si-ESR, small interfering ESR; GST, glutathione S-transferase; aa, amino acid(s); RT, reverse transcription; NS3, NS4A, NS4B, NS5A, and NS5B, nonstructural protein 3, 4A, 4B, 5A, and 5B, respectively.

## Tamoxifen Suppresses HCV NS5B-Estrogen Receptor Association

compounds that inhibited HCV replication. Using this system, we previously identified an immunosuppressant, cyclosporin A, as an anti-HCV compound (20). We also reported that cyclophilin B regulated the RNA binding activity of NS5B (21). In the current study, this chemical screening approach linked ESR $\alpha$  to HCV replication. We showed that tamoxifen (TAM) suppressed HCV genome replication. Using TAM as a bioprobe, we found that ESR $\alpha$  interacted with NS5B and regulated the participation of NS5B in the RC.

### EXPERIMENTAL PROCEDURES

**Cell Culture and Transfection**—Huh-7 and cured MH-14 cells (21) were cultured in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% fetal bovine serum, minimal essential medium nonessential amino acid (Invitrogen), and kanamycin (Meiji). MH-14 cells, carrying HCV subgenomic replicon (16), and LucNeo#2 cells, carrying luciferase-containing subgenomic replicon (22), were cultured in the same medium supplemented with 300  $\mu$ g/ml G418 (Invitrogen). Hus-E7/DN24 cells, a human hepatocyte cell line established by immortalization with HPV E6E7 and hTERT from human primary hepatocytes and introduction with a dominant negative form of interferon regulatory factor-7 (23), were cultured with Dulbecco's modified Eagle's medium with 20 mM Hepes (Invitrogen), 15 g/ml L-proline, 0.25 g/ml insulin (Sigma), 50 nM dexamethasone (Sigma), 44 mM NaHCO<sub>3</sub>, 10 mM nicotinamide, 5 ng/ml epidermal growth factor, 0.1 mM Asc-2P, 100 IU/ml penicillin G (Invitrogen), 100  $\mu$ g/ml streptomycin (Invitrogen), 5% fetal bovine serum, 1% Dulbecco's modified Eagle's medium, and 2 UG/ml Fungizone (Invitrogen) (24). Plasmid transfection was performed with FuGENE 6 transfection reagent (Roche Applied Science), as described previously (25). RNA transfection was achieved using DMrie-C transfection reagent (Invitrogen), as described previously (21). siRNA was transfected by using siLentFect (Bio-Rad) (21).

**Plasmid Construction**—pCMV-FL-ESR $\alpha$ , encoding the whole open reading frame of ESR $\alpha$  fused with a FLAG tag, was generated by inserting the PCR product using 5'-GTTGAATTCATGACCATGACCTCCAC-3' and 5'-GTTGATCTCGAGTCAGACTGTGGCAGGGAAAC-3' as primer set and human lymphocyte cDNA library (Clontech) as a template into the EcoRI-XhoI site of pCMV-FLAG vector (21). pCAG-HA-NS5B, encoding the NS5B protein fused with a hemagglutinin tag, was made by subcloning the PCR product with 5'-GTTGCGGCCGCTATGTCAATGTCCTACTCA-3' and 5'-GTTCTCGAGTCACCGTTGGGGAGCAGGTA-3' as primers and pMH14 as a template into NotI-XhoI digestion of PCAG-HA vector (21). Expression plasmids for HCV NS3, NS4B, NS5A, and NS5B (pcDNA-NS3, pcDNA-NS4B, pcDNA-NS5A, and pcDNA-NS5B, respectively) were described in Ref. 21. pGEX-ESR $\alpha$  A/B, C, D, and E/F, expressing the fusion protein of the domain A/B, C, D, and E/F of ESR $\alpha$  with GST, were prepared by the insertion of the PCR product with pCMV-FL-ESR $\alpha$  as a template and appropriate primers into the EcoRI-XhoI site of pGEX-6P1 vector (Clontech). The expression plasmids for the point mutants of ESR $\alpha$ , ESR $\alpha$ (L540Q), ESR $\alpha$ (255M), and ESR $\alpha$ (258M), of which Leu at aa 540, IRK at aa 255–257, and DRR at aa 258–260 were replaced by Gln, TGT, and ANT, respec-

tively, was generated by oligonucleotide-directed mutagenesis. pCMV-FL-CAV2, encoding FLAG-tagged CAV2, was prepared by inserting the PCR product amplified with 5'-GTTGTCGACTATGGGGCTGGAGAC-3' and 5'-GTTAAGCTTTCAATCCTGGCTC-3' as primers and human liver cDNA library (Clontech) as a template into the SalI-HindIII site of pCMV-FLAG vector (21). The mammalian expression vector for the C domain of ESR $\alpha$  was generated by replacing the EcoRI-XhoI digestion of pCMV-FLAG vector (21) by that of pGEX-ESR $\alpha$  C. pLMH14 was described previously (26). pGL3-EREX3-TATA-Luc, pcDNA3-ER $\alpha$ , pcDNA3-HER $\beta$  were kindly provided by Dr. Kato (Institute of Molecular and Cellular Biosciences, University of Tokyo). JFH1 expression plasmid was provided by Dr. Wakita (National Institute of Infectious Diseases).

**Luciferase Assay**—A luciferase assay monitoring HCV replication activity was performed as described previously (22, 26). In Fig. 1, A and F, we used LucNeo#2 cells, stably carrying luciferase-containing subgenomic replicon (22). In Figs. 2 (D and E), 4C, and 6A, we transiently transduced luciferase-containing replicon LMH14 RNA together with each expression plasmid into cured MH-14 cells (26). A luciferase assay detecting the transcriptional activity driven from the ERE was performed as described previously (25).

**Real Time RT-PCR Analysis**—Real time RT-PCR analysis was performed as previously described (20).

**Immunoblot Analysis**—Immunoblot analysis was performed as previously described (25). The antibodies used in this study are anti-NS5A (kindly provided by Dr. Takamizawa (Osaka University)), anti-NS5B (anti-NS5B#14; a generous gift from Dr. Kohara (Tokyo Metropolitan Institute of Medical Science)), anti-NS5B (NS5B#6; a kind gift from Dr. Fukuya (Osaka University)), anti-tubulin (Oncogene), anti-FLAG (Sigma), anti- $\kappa$ B $\alpha$  (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), anti-calnexin (StressGen), and anti-caveolin-2 antibodies (BD Biosciences Pharmingen).

**Indirect Immunofluorescence Analysis**—Indirect immunofluorescence analysis was performed as described previously (25). The antibodies used were anti-NS5A and anti-protein-disulfide isomerase antibodies (StressGen).

**siRNA**—siRNA duplexes (5'-GUGUGCAAUGACUAUGC-UUCA-3' for si-ESR $\alpha$  and 5'-CGCAUCGGGAUAUCACUA-UGG-3' for si-ESR $\beta$ ) were synthesized (Prologo). A randomized siRNA, si-control, was purchased from Dharmacon (nonspecific control duplex IX).


**Enzyme-linked Immunosorbent Assay**—HCV core was quantified in the culture medium of the cells transfected with JFH1 RNA (29) with an enzyme-linked immunosorbent assay according to the manufacturer's protocol (HCV antigen enzyme-linked immunosorbent assay test; Ortho-Clinical Diagnostics).

**RT-PCR Analysis**—RT-PCR analysis was performed as described (20) by using the following primer sets: 5'-CCTACTA-CCTGGAGAACG-3' and 5'-GCTGGACACATATAGTCG-3' for the detection of ESR $\alpha$  and 5'-AGCCATGACATTCTAT-AGC-3' and 5'-CCACTTCGTAACACTTCC-3' for ESR $\beta$ .

**GST Pull-down Assay**—The GST pull-down assay was conducted as described previously (25).

**Immunoprecipitation Analysis**—Immunoprecipitation analysis was performed as described previously (25). The antibodies

## Tamoxifen Suppresses HCV NSSB-Estrogen Receptor Association



**FIGURE 1. TAM suppressed the replication of the HCV genome.** *A*, luciferase activities were measured using the LucNeo#2 cells, which carried a luciferase-containing replicon RNA, upon treatment with TAM at the indicated doses for 7 days. Relative luciferase activities are plotted against the concentrations of TAM. The data show the means of three independent experiments. The error bars are indicated. *B*, HCV RNA was quantified by real time RT-PCR analysis using the lysates from MH-14 cells, harboring the HCV subgenomic replicon, treated with the indicated doses of TAM for 7 days. Relative amounts of HCV RNA are shown. *C*, HCV NSSA and NSSB proteins as well as tubulin as an internal control were detected by immunoblot analysis in the lysates from MH-14 cells (replicon) treated without (control) or with 500 nM TAM or 100 IU/ml interferon- $\alpha$  as a positive control for 7 days and Huh-7 cells. *D*, HCV NSSA and protein-disulfide isomerase (*PDI*) as an internal control were detected by indirect immunofluorescence analysis in the cells treated without (control) or with 500 nM TAM for 7 days. 4',6-Diamidino-2-phenylindole (*DAPI*) shows a nuclear staining. *E*, cell number was counted after 5 days upon treatment with various concentrations of TAM. Relative cell numbers are shown. *F*, luciferase activities with LucNeo#2 cells treated with various concentrations of ICI182780 were measured as described in *A*. *G*, cell number was counted under treatment with ICI182780 at the indicated concentrations. *H*, core in the culture medium of JFH1 RNA-transfected cells upon treatment with TAM was quantified as described under "Experimental Procedures."

used in this study were mouse normal IgG as a negative control (Zymed Laboratories), anti-NS5B (anti-NS5B#10; a generous gift from Dr. Kohara at the Tokyo Metropolitan Institute of Medical Science), anti-FLAG, and anti-caveolin-2 antibodies.

**Fractionation of Cell Extracts**—MH-14 cells transfected with the expression plasmid for FLAG-tagged ESR $\alpha$  were fractionated essentially as described previously (25).

**HCV Replication Complex Assay**—Isolation of HCV RC was done as described previously (16, 21).

**In Vitro HCV Infection Experiment**—*In vitro* HCV infection was conducted essentially as described (23). Briefly, HCV-infected serum ( $\sim 2 \times 10^5$  copies) was inoculated into HuS-E7/DN24 cells ( $5 \times 10^4$  cells) for 24 h. After washes, cells were cultured in the medium supplemented with 10  $\mu$ M PD98059 to stimulate HCV translation (27) (scheme in Fig. 6B). To observe HCV amplification, HCV RNA in the cells was quantified, since HCV RNA was hardly detected significantly in the culture medium (23).

**3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Assay**—The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was performed to examine the

cell viability using Cell Proliferation kit II, XTT (Roche Applied Science) according to the manufacturer's protocol.

### RESULTS

#### Tamoxifen Suppressed HCV Genome Replication

We screened for agents that suppressed HCV genome replication using a HCV subgenomic replicon system (13, 16). Among the compounds tested, we observed that TAM inhibited HCV genome replication. HCV replication activity, monitored by luciferase activity (22), and the amount of HCV RNA were decreased with TAM treatment in a dose-dependent manner (Fig. 1, *A* and *B*). The expression of HCV proteins, NSSA and NSSB, detected by immunoblot (Fig. 1C) and indirect immunofluorescence analyses (Fig. 1D), also drastically decreased by treatment with TAM. A high concentration of TAM decreased cell proliferation (Fig. 1E). However, TAM suppressed HCV replication without any cytotoxicity in another cell line, HuS-E7/DN24 cells (Fig. 6, *C* and *D*). In addition, a pure anti-estrogen compound ICI182780, which had little cytotoxic effect, reduced HCV RNA (Fig. 1, *F* and *G*). Moreover, TAM inhibited the production of core in the culture medium of HCV JFH1-transfected cells, in a recently


developed system of the production of infectious HCV particles (Fig. 1H) (28–30). The above data indicate that TAM suppresses HCV genome replication.

**ESR Was Involved in HCV Genome Replication**—Next, we investigated which cellular protein TAM targets to suppress HCV replication. It has been reported that TAM targets 1) ESR (31), 2) P-glycoprotein (32, 33), 3) calmodulin (34), 4) protein kinase C (35, 36), etc. Although other compounds targeting P-glycoprotein, calmodulin, and protein kinase C did not affect HCV replication in our screening (data not shown), ESR was suggested to play a role in HCV replication as shown below.

RNAi-mediated specific knockdown of endogenous ESR $\alpha$  and ESR $\beta$  (Fig. 2A) reduced HCV RNA in replicon-containing cells to  $\sim 20$ –40% and 60–70%, respectively (Fig. 2B). Transient transfection with ESR $\alpha$  and ESR $\beta$  expression plasmids, which activated ERE-driven transcription 4–5-fold (Fig. 2C), showed that ectopically expressed ESR $\alpha$  augmented HCV replication activity in a dose-dependent manner, whereas ESR $\beta$  did not (Fig. 2D). ESR $\alpha$ -induced augmentation of the replication was reversed upon TAM treatment (Fig. 2D). These results suggested a significant role of ESR, especially ESR $\alpha$ , in HCV




## Tamoxifen Suppresses HCV NSSB-Estrogen Receptor Association



**FIGURE 2. ESR was involved in HCV genome replication.** A, specific knock-down of endogenous ESR $\alpha$  and ESR $\beta$ . RT-PCR analysis was performed to detect the expression of ESR $\alpha$ , ESR $\beta$ , and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an internal control in the cells transfected with siRNA recognizing ESR $\alpha$  (si-ESR $\alpha$ , si-ESR $\alpha$ 2), ESR $\beta$  (si-ESR $\beta$ , si-ESR $\beta$ 2), or randomized siRNA (si-control, si-control2). B, HCV RNA was quantified as shown in Fig. 1B, using the cells transfected with si-control, si-control2, si-ESR $\alpha$ , si-ESR $\alpha$ 2, si-ESR $\beta$ , and si-ESR $\beta$ 2 for 5 days. C, the ERE-mediated transcriptional activities were measured by a luciferase assay using the lysates from the cells transfected with pGL3-ERE3-TATA-Luc reporter plasmid together with pcDNA3-ER $\alpha$  (ESR $\alpha$ ), pcDNA3-hER $\beta$  (ESR $\beta$ ), pcDNA-ESR $\alpha$ (L540Q), or the empty vector (control) (left) or varying amounts (ng) of pcDNA3-ER $\alpha$  (ESR $\alpha$ ) or pcDNA-ESR $\alpha$ (L540Q) (right) and treated with 100 nM estradiol for 36 h. D and E, HCV replication activities were examined by quantifying the luciferase activities using cured MH-14 cells transfected with the indicated doses (ng) of ESR $\alpha$  or ESR $\beta$  (D) or 30 ng of ESR $\alpha$ , ESR $\alpha$ (L540Q), or the empty vector (control) (E) together with 0.125  $\mu$ g of LMH14 RNA without or with 1  $\mu$ M TAM for 4 days.

genome replication. ESR $\alpha$ (L540Q), carrying a leucine to glutamine point mutation at aa 540 within the LXXLL motif (aa 536–540) of ESR $\alpha$  (37), had much lower transactivation activity driven from ERE (Fig. 2C). However, ESR $\alpha$ (L540Q) stimulated HCV replication activity ~5-fold, although the stimulation was less than that by wild-type ESR $\alpha$  (Fig. 2E). Thus, ESR $\alpha$  having lower transactivating capacity could still facilitate HCV replication.

**ESR $\alpha$  Interacted with HCV NSSB**—Thus, the chemical biology approach revealed the involvement of ESR in HCV genome replication. Then we investigated the molecular mechanism of ESR-induced HCV replication. A binding assay between ESR $\alpha$  and HCV proteins expressed in the HCV subgenomic replicon showed that the C domain of ESR $\alpha$  coprecipitated with NSSB but not NS3, NS4B, and NS5A (Fig. 3A). Other ESR $\alpha$  domains, A/B, D, and E/F, did not bind to any HCV proteins. A coimmunoprecipitation assay also indicated the presence of ESR $\alpha$  in the




**FIGURE 3. ESR $\alpha$  interacted with HCV NSSB.** A, top, schematic representation of the primary structure of ESR $\alpha$ . ESR $\alpha$  consists of domains A–F. The amino acid numbers are also shown. Bottom, GST pull-down assays were performed using the recombinant proteins of the A/B, C, D, and E/F domain of ESR $\alpha$  fused with GST and *in vitro* translated HCV NS3, NS4B, NSSA, and NSSB protein. Input, the one-fifth amount of protein used for the pull-down assay. The Coomassie Brilliant Blue staining pattern of the precipitated fraction is also shown in the bottom panel. B–D, the lysates from the cells ectopically expressing NSSB (B and C) or the whole open reading frame of the HCV JFH1 strain (D) and/or FLAG-tagged ESR $\alpha$  were immunoprecipitated (IP) with anti-NSSB (B; NSSB), anti-FLAG antibody (C and D; FL), or mouse normal IgG as a negative control followed by the detection of ESR $\alpha$  and NSSB by immunoblot analysis (IB). E, deletion mutants of NSSB were subjected to a GST pull-down assay with GST-fused C domain of ESR $\alpha$  as described in A. The left panel shows a schematic representation of the full-length and truncated mutants of NSSB. The numbers indicate the amino acid numbers in NSSB.

immunoprecipitate by anti-NSSB antibody (Fig. 3, B and D), and *vice versa* (Fig. 3C). Thus, ESR $\alpha$  specifically interacted with NSSB. Deletion analysis indicated that the region of 71–591 and 1–520 but not 521–591 of NSSB coprecipitated with the recombinant C domain of ESR $\alpha$  (Fig. 3E). This binding profile is different from that between cyclophilin B and NSSB, which we previously reported (21).

**The ESR $\alpha$ -NSSB Interaction Was Important for the Regulation of HCV Genome Replication**—To examine whether the interaction between ESR $\alpha$  and NSSB was essential for the ESR $\alpha$ -mediated regulation of HCV replication or not, we searched for a point mutant of ESR $\alpha$  that could not bind to NSSB by alanine-scanning mutation analysis. ESR $\alpha$  mutants, ESR $\alpha$ (255M) and ESR $\alpha$ (258M), in which IRK at aa 255–257 and DRR at aa 258–260 was replaced by TGT and AQT, respectively, had little affinity with NSSB (Fig. 4A) but still possessed the ERE-mediated transactivation capacity (Fig. 4B). However, both ESR $\alpha$ (255M) and ESR $\alpha$ (258M) caused only weak activations of HCV replication, compared with wild type ESR $\alpha$  (Fig. 4C). The data suggest that the interaction of ESR $\alpha$  with NSSB is





**FIGURE 4. The interaction of NS5B mediated the regulation of HCV genome replication by ESR $\alpha$ .** A, GST pull-down assays were performed as described in Fig. 3A using the wild type ESR $\alpha$  or point mutant of ESR $\alpha$ , ESR $\alpha$ (255M), and ESR $\alpha$ (258M). B, the mutation within ESR $\alpha$ (255M) and ESR $\alpha$ (258M) did not reduce the activation capacity of ERE-mediated transcription. Huh-7 cells were transfected with the expression plasmids for ESR $\alpha$ , ESR $\alpha$ (255M), or ESR $\alpha$ (258M) at doses of 10, 30, and 100 ng each together with pGL3-ERE3-TATA-Luc reporter plasmid and treated without (white bar) or with 100 nM estradiol (black bar) to quantify the luciferase activity. C, HCV replication activities were examined by quantifying the luciferase activities as described in the legend to Fig. 2D in the cells upon transfection with the expression plasmids for wild type ESR $\alpha$ , ESR $\alpha$ (255M), or ESR $\alpha$ (258M). D, the cells were fractionated into the nucleus (N), MM, and cytoplasm (C). Each fraction was detected for FLAG-tagged ESR $\alpha$ , SC-35, calnexin, and I $\kappa$ B $\alpha$ , respectively, by immunoblot analysis. Calnexin, an ER marker protein, was detected in the nucleus as well as MM, probably because of the existence of the nuclear membrane in the nuclear fraction. E, the MM fraction obtained in D was subjected to a coimmunoprecipitation assay using anti-NS5B or IgG followed by immunoblot analysis for the detection for ESR $\alpha$ .

critical for ESR $\alpha$ -mediated regulation of HCV genome replication.


Thus, ESR $\alpha$  interaction with NS5B regulates HCV replication. NS5B is mainly located on the cytoplasmic surface of the ER membrane (21, 38). On the other hand, ESR $\alpha$  as a nuclear hormone receptor is normally distributed in the cytoplasm and translocates into the nucleus upon ligand stimulation. In addition, a part of ESR $\alpha$  localizes on the membrane fraction. In our experiment, NS5B was mainly located around the ER, colocalized with the ER marker, protein-disulfide isomerase (data not shown) (21). Ectopically expressed ESR $\alpha$  showed diffuse distribution in the cells (data not shown). We fractionated cell homogenates and observed that a part of the ESR $\alpha$  resided in the microsomal membrane (MM) fraction (Fig. 4D). Moreover, ESR $\alpha$  in the MM fraction was coprecipitated with NS5B (Fig. 4E). It suggests the possibility that the interaction between NS5B and ESR $\alpha$ , at least in part of them, occurs on the ER membrane.

**ESR $\alpha$  Promoted the Participation of NS5B in the HCV Replication Complex**—It was reported that HCV proteins involved in the replication machinery was associated with the lipid raft on the ER and cofractionated with CAV2. A coimmunoprecipitation assay showed that NS5B associated with CAV2 (Fig. 5A).


In the experiment investigating the role of ESR $\alpha$  in NS5B-CAV2 association, the coprecipitation of NS5B with CAV2 was decreased upon the knocking down of ESR $\alpha$  (Fig. 5B). Treatment with TAM abrogated the association of NS5B with CAV2 (Fig. 5C), although the total amount of NS5B in the cells is similar in the presence and absence of TAM for 24 h in this experiment (data not shown). Thus, ESR $\alpha$  was suggested to promote the association between NS5B and CAV2. Since a part of CAV2 resided on the lipid raft on the ER (18), ESR $\alpha$ -mediated binding between NS5B and CAV2 was possible to affect the localization of NS5B to the HCV RC. To see the consequential relevance of ESR $\alpha$  on NS5B function, we analyzed the HCV RC by treatment with digitonin/protease as described previously (16). HCV proteins involved in the RC and surrounded by the membrane structure are resistant to the treatment with digitonin followed by protease, whereas those unrelated to the replication outside the RC are digested by the treatment. By using this technique measuring the sensitivity to protease, HCV RC can be distinguished from the ER that is not related to the replication, although the RC and the nucleus cannot be separated. The experimental condition for fractionation was confirmed with the detection with I $\kappa$ B $\alpha$  and calnexin; a cytosolic protein I $\kappa$ B $\alpha$  was washed out following the treatment with digitonin (Fig. 5D, lanes 1 and 2), and ER protein calnexin, which did not accumulate in the RC, was digested by treatment with digitonin/protease (Fig. 5D, lanes 2–4). An ER lipid raft component, CAV2, was still detected under the digitonin/protease treatment (the RC-containing fraction) (Fig. 5D, lanes 3 and 4). Under this condition, a part of NS5B was detected in the digitonin/protease-resistant fraction, as described previously (16) (Fig. 5D, lanes 3 and 4). However, NS5B in this fraction was decreased upon treatment with TAM (Fig. 5D, lanes 3, 4, 7, and 8). On the other hand, the amount of NS5A was not significantly changed by TAM treatment. Knocking down of ESR $\alpha$  also disrupted the association of NS5B with the RC-containing fraction (Fig. 5E). From the above results, it was suggested that ESR $\alpha$  promoted the participation of NS5B in the RC (also see “Discussion”).

**ESR $\alpha$  Could Serve as a Molecular Target of Anti-HCV Agents**—Finally, we assessed the possibility that the association of ESR $\alpha$  with NS5B could serve as a target of anti-HCV agents. By introducing a decoy peptide against ESR $\alpha$ -NS5B interaction, consisting of the C domain of ESR $\alpha$  into replicon-bearing cells,

## Tamoxifen Suppresses HCV NS5B-Estrogen Receptor Association



**FIGURE 5. ESR $\alpha$  promoted the participation of NS5B in HCV RC.** A–C, a coimmunoprecipitation assay (IP) was performed with anti-FLAG (A), anti-CAV2 (B and C) antibody, or mouse normal IgG from the lysates of the cells transfected without or with FLAG-tagged CAV2 (A), transfected with si-control or si-ESR $\alpha$  (B), or treated without or with 1  $\mu$ M TAM (C). NS5B (top) and CAV2 (bottom) were detected by immunoblot analysis. D, detection of the amount of NS5B in the digitonin/protease-resistant fraction. MH-14 cells were treated without (lanes 1–4) or with 1  $\mu$ M TAM (lanes 5–8) for 24 h. Cells were then treated without (lanes 1 and 5) or with digitonin (lanes 2–4 and 6–8), followed by digestion with proteinase K (0  $\mu$ g/ml for lanes 2 and 6, 0.3  $\mu$ g/ml for lanes 3 and 7, and 1  $\mu$ g/ml for lanes 4 and 8). NS5B, NSSA, I $\kappa$ B, calnexin, and CAV2 were detected by immunoblot analysis. E, HCV RC was isolated as described in D using the cells transfected with si-control or si-ESR $\alpha$ , and NS5B was detected. A similar result was obtained by using si-ESR $\alpha$ 2.



**FIGURE 6. ESR $\alpha$  could serve as a molecular target for anti-HCV agents.** A, HCV replication activity was measured by quantifying the luciferase activity as described in the legend to Fig. 2D in the cells overexpressing a decoy peptide consisting of the C domain of ESR $\alpha$ . B, experimental scheme of *in vitro* HCV infection experiment. After seeding the HuS-E7/DN24 cells, HCV-positive serum was inoculated for 24 h. After extensive washes, the cells were cultured with the medium supplemented without (control) or with 1  $\mu$ M TAM or 3  $\mu$ g/ml cyclosporin A. HCV genome RNA was quantified along with the time course (days 1, 3, and 5 postinoculation) by real time RT-PCR analysis. C, the treatment with 1  $\mu$ M TAM did not show any cytotoxic effect on HuS-E7/DN24 cells. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays were performed as described under "Experimental Procedures" to examine the viability of the cells at days 2, 3, and 5 postinoculation. D, HCV genome RNA was quantified as described in B and plotted against the time course.

HCV replication activity was reduced in a dose-dependent manner (Fig. 6A). To further observe the significance of ESR $\alpha$  in a physiological condition, we performed an *in vitro* infection experiment using serum from an HCV-infected patient as a nascent virus inoculum and nonneoplastic human hepatocytes as highly infection-permissive cells (Fig. 6B). Treatment with 1  $\mu$ M TAM did not show a cytotoxic effect on these cells in any time course examined (Fig. 6C). However, treatment with TAM as well as cyclosporin A as a positive control inhibited the multiplication of viral genome RNA in the cells along with the time course (Fig. 6D). Thus, ESR $\alpha$  could serve as a potent molecular target of anti-HCV agents.

## DISCUSSION

In general, viruses take advantage of host cell factors for their replication. So far, some factors have been shown to relevantly regulate HCV replication, including hVAP33 (39, 40), FBL2 (41), and cyclophilin B (21). Among these, FBL2 and cyclophilin B were identified by a chemical biological approach; FBL2 from the observation of an anti-HCV activity of lovastatin and an inhibitor of geranylgeranyl transferase (41–43); cyclophilin B from the inhibitory effect of cyclosporin A on HCV replication (20, 21). In this study, we found a suppressive capacity of TAM to HCV genome replication. Through further examination using TAM, we revealed ESR $\alpha$  as a host cell factor regulating HCV replication and suggested its regulation mechanism.

Currently, it is proposed that HCV RC that replicates the HCV genome is formed on the intracellular membrane, including the ER membrane (14–17). It was also reported that HCV genome replication was associated with the lipid raft on the intracellular membrane (18). Most HCV proteins are not related to the RC, whereas only a minor portion of HCV proteins take part in the RC to drive the viral replication (16). It has remained widely unknown, however, how HCV proteins are regulated to participate in the RC. It was reported that hVAP-33 binds to NS5A and NS5B, and this protein is related to the amount of NS5B in the lipid raft (40). hVAP-33 was speculated to recruit NS5B to the lipid raft, although its molecular mechanism has not been analyzed. This study suggested the interaction between ESR $\alpha$  and NS5B in the ER fraction, although we did not show the existence of ESR $\alpha$  in the RC, since the RC and the nucleus cannot be separated in the digitonin/protease treatment experiment. ESR $\alpha$  promoted the interaction of NS5B with CAV2. Previous papers reported that ESR $\alpha$  bound to CAV1 and CAV2 (6). From these observations, ESR $\alpha$  is

likely to function as a bridging factor that connects NS5B to CAV2, although we cannot fully neglect the possibility that ESR $\alpha$  augments NS5B-CAV2 binding via another function, such as transcriptional activity. Because CAV2 resided on the lipid raft of the intracellular membrane (18), this action of ESR $\alpha$  may recruit NS5B to the lipid raft and the HCV RC. In fact, ESR $\alpha$  promoted the participation of NS5B in the HCV RC. Thus, ESR $\alpha$  is suggested to escort NS5B to the HCV RC, although it is also possible that ESR $\alpha$  augments the number of the RC itself. However, ESR $\alpha$  at least augments the amount of NS5B involved in HCV replication machinery to stimulate the replication. It was reported that the membrane-associated ESR $\alpha$  served as a platform where signalsomes, including receptor tyrosine kinase, nonreceptor tyrosine kinase Src, and G proteins, assembled and activated downstream signaling pathways (44–46). HCV may also take advantage of such platform characteristics of ESR $\alpha$  to form the RC for their efficient replication. Although the mechanisms of the nuclear receptor function of ESR $\alpha$  have been extensively elucidated, the functions of membrane-associated ESR $\alpha$  have not been widely characterized so far. This study suggested a novel physiological relevance of membrane-associated ESR $\alpha$  as a regulator of the viral replication.

Until now, there are no clinical studies that report a direct interaction of TAM treatment with HCV replication in patients infected with HCV. Given our results, examinations on the effect of TAM or other anti-estrogen drugs may be one of the useful approaches to develop a new anti-HCV strategy. On the other hand, we disclosed the mechanism of ESR-mediated regulation of HCV genome replication. Screening for compounds that inhibit this mechanism expectedly led to novel types of anti-HCV agents. Further analyses on ESR are needed to develop anti-HCV therapeutics as well as reveal the regulation mechanism of HCV replication.

**Acknowledgments**—We are grateful to Dr. T. Murata, T. Hishiki, and M. Hosaka for establishing the replicon-containing cells. We thank Dr. Aratake (Asahi Kasei Pharma) for helpful discussions. We also thank Dr. Kato, Dr. Takamizawa, Dr. Kohara, Dr. Fukuya, and Dr. Wakita for kindly providing the plasmids: pGL3-EREK3-TATA-Luc, pcDNA3-ER $\alpha$ , and pcDNA3-hER $\beta$ ; anti-NS5A antibody; anti-NS5B antibody; anti-NS5B antibody; and JFH1 expression plasmid, respectively.

REFERENCES

1. Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., and Evans, R. M. (1995) *Cell* **83**, 835–839
2. Acconcia, F., and Kumar, R. (2006) *Cancer Lett.* **238**, 1–14
3. Levin, E. R. (2005) *Mol. Endocrinol.* **19**, 1951–1959
4. Song, R. X., Zhang, Z., and Santen, R. J. (2005) *Trends Endocrinol. Metab.* **16**, 347–353
5. Razandi, M., Alton, G., Pedram, A., Ghonshani, S., Webb, P., and Levin, E. R. (2003) *Mol. Cell. Biol.* **23**, 1633–1646
6. Razandi, M., Oh, P., Pedram, A., Schnitzer, J., and Levin, E. R. (2002) *Mol. Endocrinol.* **16**, 100–115
7. Marquez, D. C., Chen, H. W., Curran, E. M., Welshons, W. V., and Pietras,

- R. J. (2006) *Mol. Cell. Endocrinol.* **246**, 91–100
8. Liang, T. J., Jeffers, L. J., Reddy, K. R., De Medina, M., Parker, I. T., Cheinquer, H., Idrovo, V., Rabassa, A., and Schiff, E. R. (1993) *Hepatology* **18**, 1326–1333
9. Grakoui, A., Wychowski, C., Lin, C., Feinstone, S. M., and Rice, C. M. (1993) *J. Virol.* **67**, 1385–1395
10. Hijikata, M., Kato, N., Ootsuyama, Y., Nakagawa, M., and Shimotohno, K. (1991) *Proc. Natl. Acad. Sci. U. S. A.* **88**, 5547–5551
11. Bartenschlager, R., and Lohmann, V. (2001) *Antiviral Res.* **52**, 1–17
12. Tellinghuisen, T. L., and Rice, C. M. (2002) *Curr. Opin. Microbiol.* **5**, 419–427
13. Lohmann, V., Korner, F., Koch, J., Herian, U., Theilmann, L., and Bartenschlager, R. (1999) *Science* **285**, 110–113
14. Aizaki, H., Lee, K. J., Sung, V. M., Ishiko, H., and Lai, M. M. (2004) *Virology* **324**, 450–461
15. Egger, D., Wolk, B., Gosert, R., Bianchi, L., Blum, H. E., Moradpour, D., and Bienz, K. (2002) *J. Virol.* **76**, 5974–5984
16. Miyanari, Y., Hijikata, M., Yamaji, M., Hosaka, M., Takahashi, H., and Shimotohno, K. (2003) *J. Biol. Chem.* **278**, 50301–50308
17. Moradpour, D., Gosert, R., Egger, D., Penin, F., Blum, H. E., and Bienz, K. (2003) *Antiviral Res.* **60**, 103–109
18. Shi, S. T., Lee, K. J., Aizaki, H., Hwang, S. B., and Lai, M. M. (2003) *J. Virol.* **77**, 4160–4168
19. Watashi, K., and Shimotohno, K. (2007) *Rev. Med. Virol.* **17**, 245–252
20. Watashi, K., Hijikata, M., Hosaka, M., Yamaji, M., and Shimotohno, K. (2003) *Hepatology* **38**, 1282–1288
21. Watashi, K., Ishii, N., Hijikata, M., Inoue, D., Murata, T., Miyanari, Y., and Shimotohno, K. (2005) *Mol. Cell* **19**, 111–122
22. Goto, K., Watashi, K., Murata, T., Hishiki, T., Hijikata, M., and Shimotohno, K. (2006) *Biochem. Biophys. Res. Commun.* **343**, 879–884
23. Aly, H. H., Watashi, K., Hijikata, M., Kaneko, H., Takada, Y., Egawa, H., Uemoto, S., and Shimotohno, K. (2007) *J. Hepatol.* **46**, 26–36
24. Hino, H., Tateno, C., Sato, H., Yamasaki, C., Katayama, S., Kohashi, T., Aratani, A., Asahara, T., Dohi, K., and Yoshizato, K. (1999) *Biochem. Biophys. Res. Commun.* **256**, 184–191
25. Watashi, K., Hijikata, M., Tagawa, A., Doi, T., Marusawa, H., and Shimotohno, K. (2003) *Mol. Cell. Biol.* **23**, 7498–7509
26. Murata, T., Ohshima, T., Yamaji, M., Hosaka, M., Miyanari, Y., Hijikata, M., and Shimotohno, K. (2005) *Virology* **331**, 407–417
27. Murata, T., Hijikata, M., and Shimotohno, K. (2005) *Virology* **340**, 105–115
28. Lindenbach, B. D., Evans, M. J., Syder, A. J., Wolk, B., Tellinghuisen, T. L., Liu, C. C., Maruyama, T., Hynes, R. O., Burton, D. R., McKeating, J. A., and Rice, C. M. (2005) *Science* **309**, 623–626
29. Wakita, T., Pietschmann, T., Kato, T., Date, T., Miyamoto, M., Zhao, Z., Murthy, K., Habermann, A., Krausslich, H. G., Mizokami, M., Bartenschlager, R., and Liang, T. J. (2005) *Nat. Med.* **11**, 791–796
30. Zhong, J., Gastaminza, P., Cheng, G., Kapadia, S., Kato, T., Burton, D. R., Wieland, S. F., Uprichard, S. L., Wakita, T., and Chisari, F. V. (2005) *Proc. Natl. Acad. Sci. U. S. A.* **102**, 9294–9299
31. Shang, Y. (2006) *Nat. Rev. Cancer* **6**, 360–368
32. Callaghan, R., and Higgins, C. F. (1995) *Br. J. Cancer* **71**, 294–299
33. Raderer, M., and Scheithauer, W. (1993) *Cancer* **72**, 3553–3563
34. Lopes, M. C., Vale, M. G., and Carvalho, A. P. (1990) *Cancer Res.* **50**, 2753–2758
35. O'Brian, C. A., Liskamp, R. M., Solomon, D. H., and Weinstein, I. B. (1985) *Cancer Res.* **45**, 2462–2465
36. O'Brian, C. A., Ward, N. E., and Anderson, B. W. (1988) *J. Natl. Cancer Inst.* **80**, 1628–1633
37. Leers, J., Treuter, E., and Gustafsson, J. A. (1998) *Mol. Cell. Biol.* **18**, 6001–6013
38. Schmidt-Mende, J., Bieck, E., Hugle, T., Penin, F., Rice, C. M., Blum, H. E., and Moradpour, D. (2001) *J. Biol. Chem.* **276**, 44052–44063
39. Evans, M. J., Rice, C. M., and Goff, S. P. (2004) *Proc. Natl. Acad. Sci. U. S. A.* **101**, 13038–13043
40. Gao, L., Aizaki, H., He, J. W., and Lai, M. M. (2004) *J. Virol.* **78**, 3480–3488
41. Wang, C., Gale, M., Jr., Keller, B. C., Huang, H., Brown, M. S., Goldstein, J. L., and Ye, J. (2005) *Mol. Cell* **18**, 425–434

## Tamoxifen Suppresses HCV NS5B-Estrogen Receptor Association

42. Kapadia, S. B., and Chisari, F. V. (2005) *Proc. Natl. Acad. Sci. U. S. A.* **102**, 2561–2566
43. Ye, J., Wang, C., Sumpter, R., Jr., Brown, M. S., Goldstein, J. L., and Gale, M., Jr. (2003) *Proc. Natl. Acad. Sci. U. S. A.* **100**, 15865–15870
44. Migliaccio, A., Piccolo, D., Castoria, G., Di Domenico, M., Bilancio, A., Lombardi, M., Gong, W., Beato, M., and Auricchio, F. (1998) *EMBO J.* **17**, 2008–2018
45. Razandi, M., Pedram, A., Greene, G. L., and Levin, E. R. (1999) *Mol. Endocrinol.* **13**, 307–319
46. Wyckoff, M. H., Chambliss, K. L., Mineo, C., Yuhanna, I. S., Mendelsohn, M. E., Mumby, S. M., and Shaul, P. W. (2001) *J. Biol. Chem.* **276**, 27071–27076

# The lipid droplet is an important organelle for hepatitis C virus production

Yusuke Miyanari<sup>1,2</sup>, Kimie Atsuzawa<sup>3</sup>, Nobuteru Usuda<sup>3</sup>, Koichi Watashi<sup>1,2</sup>, Takayuki Hishiki<sup>1,2</sup>, Margarita Zayas<sup>4</sup>, Ralf Bartenschlager<sup>4</sup>, Takaji Wakita<sup>5</sup>, Makoto Hijikata<sup>1,2</sup> and Kunitada Shimotohno<sup>1,2,5</sup>

**The lipid droplet (LD) is an organelle that is used for the storage of neutral lipids. It dynamically moves through the cytoplasm, interacting with other organelles, including the endoplasmic reticulum (ER)<sup>1–3</sup>. These interactions are thought to facilitate the transport of lipids and proteins to other organelles. The hepatitis C virus (HCV) is a causative agent of chronic liver diseases<sup>4</sup>. HCV capsid protein (Core) associates with the LD<sup>5</sup>, envelope proteins E1 and E2 reside in the ER lumen<sup>6</sup>, and the viral replicase is assumed to localize on ER-derived membranes. How and where HCV particles are assembled, however, is poorly understood. Here, we show that the LD is involved in the production of infectious virus particles. We demonstrate that Core recruits nonstructural (NS) proteins and replication complexes to LD-associated membranes, and that this recruitment is critical for producing infectious viruses. Furthermore, virus particles were observed in close proximity to LDs, indicating that some steps of virus assembly take place around LDs. This study reveals a novel function of LDs in the assembly of infectious HCV and provides a new perspective on how viruses usurp cellular functions.**


Hepatitis C virus (HCV) has a plus-strand RNA genome that encodes the viral structural proteins Core, E1 and E2, the p7, and the nonstructural (NS) proteins 2, 3, 4A, 4B, 5A and 5B (refs 7, 8). NS proteins are reported to localize on the cytoplasmic side of endoplasmic reticulum (ER) membranes<sup>9</sup>. To elucidate the mechanisms of virus production, we used a HCV strain, JFH1, which can produce infectious viruses<sup>10–12</sup>. We first investigated the subcellular localization of the HCV proteins in cells that had been transfected with JFH1<sup>E2FL</sup> RNA, in which a part of the hypervariable region 1 of E2 was replaced by the FLAG epitope tag (see Supplementary Information, Fig. S1, S2a–d). Core localized to the lipid droplets (LDs; Fig. 1a), as previously reported<sup>5</sup>. Interestingly, NS proteins were also detected around LDs in 60–90% of JFH1<sup>E2FL</sup>-replicating cells (Fig. 1a, c). Similar levels of colocalization of LDs with viral proteins were observed in cells that had been transfected with chimeric HCV genomes

expressing structural proteins, p7 and part of NS2 of the genotype 1b (Con1) or the genotype 1a (H77) isolate (see Supplementary Information, Fig. S1, S2e)<sup>13</sup>. In contrast, there was no close association between the LDs and NS proteins in cells that had been transfected with JFH1<sup>dC3</sup> RNA (Fig. 1b, c), which lacked the coding region of Core (Supplementary Information, Fig. S1). NS proteins were diffusely present on the ER, suggesting that NS proteins are translocated from the ER to LDs in JFH1<sup>E2FL</sup>-replicating cells in a Core-dependent manner. Importantly, there was no association between LDs and PDI, an ER marker protein, indicating that either ER membranes were absent in close proximity to LDs or that PDI was excluded from such membranes (Fig. 1c). These results were supported by western blot analysis of the LD fraction (Fig. 1d). The LD fraction contained ADRP, an LD marker, but not the ER markers Calnexin and Grp78 (data not shown), indicating that there was no ER contamination in the LD fraction. However, the LD fraction from JFH1<sup>E2FL</sup>-replicating cells contained high levels of viral proteins in contrast to the LD fraction from JFH1<sup>dC3</sup>-replicating cells (in which HCV proteins were virtually absent (Fig. 1d, LD fraction)), even though the expression levels of the NS proteins in whole-cell extracts were similar (Fig. 1d, whole-cell extract). About 20–45% of the total HCV proteins associated with the LDs in JFH1<sup>E2FL</sup>-replicating cells (Fig. 1e). Consistent with previous reports that Core enhances the formation of LDs<sup>14</sup>, overproduction of LDs was observed in JFH1<sup>E2FL</sup>-, but not JFH1<sup>dC3</sup>-replicating cells (Supplementary Information, Fig. S3a–l). Treatment of the cells with oleic acid, which enhanced the formation of LDs, did not affect either HCV protein levels or the recruitment of viral proteins to LDs in JFH1<sup>dC3</sup>-replicating cells (Supplementary Information, Fig. S3m–p). Thus, the overproduction of LDs is insufficient for the recruitment of HCV proteins to LDs. To examine the ability of Core to recruit NS proteins to LDs, JFH1<sup>dC3</sup>-replicating cells were transfected with a plasmid-expressing Core (Core<sup>wt</sup>) (Fig. 1f, g). NS5A accumulated around LDs (Fig. 1f, arrowheads and panel 2), as did NS3 and NS4AB (Fig. 1g), in cells expressing Core<sup>wt</sup>. The translocation of NS proteins to LDs was, however, not observed in JFH1<sup>dC3</sup>-replicating cells expressing Core<sup>pp/AA</sup> (Fig. 1g and Supplementary Information, Fig. S2f–h),

<sup>1</sup>Department of Viral Oncology, Institute for Virus Research, Kyoto University, Kyoto 606-8507, Japan; <sup>2</sup>Graduate School of Biostudies, Kyoto University, Kyoto 606-8507, Japan; <sup>3</sup>Department of Anatomy, Fujita Health University School of Medicine, Toyoake 470-1192, Japan; <sup>4</sup>Department of Molecular Virology, University of Heidelberg, 69120 Heidelberg, Germany; <sup>5</sup>Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan  
<sup>5</sup>Correspondence should be addressed to K.S. (e-mail: shimkuni@z8.keio.jp)

Received 16 March 2007; accepted 31 July 2007; published online 26 August 2007; DOI: 10.1038/ncb1631

LETTERS




**Figure 1** Core recruits NS proteins to LDs. (a) Huh-7 cells transfected with JFH1<sup>E2FL</sup> RNA were labelled with antibodies against Core (red), NS5A (blue), NS3 (red), NS4AB (red) or NS5B (red). Lipid droplets (LDs) and nuclei were stained with BODIPY 493/503 (green) and DAPI (white in upper panel, blue in lower panels), respectively. Insets are high magnification images of areas in the respective panel. (b) JFH1<sup>ΔC3</sup> replicon-bearing cells were labelled with DAPI (blue), BODIPY 493/503 (green) and indicated antibodies (red). The insets are high magnifications of the corresponding panel. (c) Percentages of JFH1<sup>E2FL</sup>- or JFH1<sup>ΔC3</sup>-bearing cells in which hepatitis C virus (HCV) proteins or PDI colocalize with LDs ( $n > 200$ ). (d) Western blot analysis of HCV proteins and marker proteins in whole-cell extracts and the LD fractions from cells transfected with JFH1<sup>E2FL</sup> (E2FL) or JFH1<sup>ΔC3</sup> (dC3) RNA. (e) HCV proteins were quantified by using

western blotting data of the purified LD fraction and whole-cell extracts of JFH1<sup>E2FL</sup>-replicating cells. Results are shown as relative amounts of HCV proteins co-fractionated with LDs. This results correspond well with results obtained by quantitative immunofluorescence staining (data not shown). (f) Trans-complementation with Core<sup>M</sup> relocates NS proteins to LDs. JFH1<sup>ΔC3</sup> replicon-bearing cells were transfected with pcDNA3-Core<sup>M</sup> and labelled with BODIPY 493/503 (green), DAPI (white) and antibodies against NS5A (red) and Core (blue). Arrowheads indicate Core<sup>M</sup>-expressing cells. Higher-magnification images of area 1 and area 2 are shown in panels 1 and 2, respectively. Scale bars, 2  $\mu$ m. (g) The percentages of cells in which HCV proteins colocalize with LDs in the presence of Core<sup>M</sup> or Core<sup>PP3AA</sup> ( $n > 200$ ). Uncropped images of gels are shown in Supplementary Information Fig. S6. All error bars are derived from s.d.

a variant of Core containing two alanine substitutions at amino-acid positions 138 and 143 that fails to associate with LDs<sup>15</sup>. These results show that LD-associated Core recruits NS proteins from the ER to LDs.

Next, we investigated whether Core also recruited HCV RNA to LDs. *In situ* hybridization analysis showed that in more than 80% of JFH1<sup>E2FL</sup>-replicating cells, both plus- and minus-strand RNAs were diffusely



**Figure 2** Core-dependent recruitment of active HCV replication complexes to the LD. (a) Huh-7 cells transfected with JFH1<sup>E2FL</sup> RNA were analysed by *in situ* hybridization with strand-specific probes (plus or minus). The cells were labelled to simultaneously visualize lipid droplets (LDs), NS5A and Core (lower panels). Higher-magnification images of area 1 and area 2 are shown in the upper and middle right panels 1 and 2, respectively. Scale bars: 2  $\mu$ m (panels 1, 2); 10  $\mu$ m (lower right panel). (b) The percentages of JFH1<sup>E2FL</sup>-, JFH1<sup>dC3</sup>- and JFH1<sup>PP/AA</sup>-expressing cells positive for overlapping signals for LDs and plus- or minus-strand hepatitis C virus (HCV) RNA ( $n > 200$ ). (c) Intact or digitonin and nuclease-treated (dig/nuc) JFH1<sup>E2FL</sup> replicon-bearing cells were analysed


by *in situ* hybridization. The percentages of cells with overlapping signals for LD and plus- or minus-strand HCV RNA are shown ( $n > 200$ ). (d) RNA-synthesizing activity in the LD fractions purified from cells transfected with JFH1<sup>E2FL</sup>, JFH1<sup>dC3</sup> or JFH1<sup>PP/AA</sup> RNA (top panel). As a control, HCV RNA synthesis activity in digitonin-permeabilized cells was analysed (second panel from the top). HCV protein levels represented by NS5A are shown, together with the level of tubulin (bottom two panels). (e) Localization of plus-strand HCV RNA and Core in JFH1<sup>dC3</sup> replicon-bearing cells transfected with pcDNA3-Core<sup>W1</sup> (Scale bar, 10  $\mu$ m). Uncropped images of gels are shown in Supplementary Information Fig. S6. All error bars are derived from s.d.

located in the perinuclear region (see Supplementary Information, Fig. S4a). More importantly, in about 20% of these cells, plus- and minus-strand RNAs accumulated around LDs (Fig. 2a, upper and middle panels; 2b) and colocalized with HCV proteins such as Core and NS5A (Fig. 2a, lower panels). No association between HCV RNA and LDs was detected in JFH1<sup>dC3</sup>- or JFH1<sup>PP/AA</sup>-replicating cells (Fig. 2b). Northern blot analysis revealed that 4.8% and 5.4% of total plus- and minus-strand HCV RNA, respectively, were detected in purified LD fractions of JFH1<sup>E2FL</sup>-replicating cells (data not shown). Induction of LD formation with oleic acid did not affect HCV RNA accumulation around LDs (data not shown). These results provide strong evidence that Core recruits HCV RNA as well as NS proteins to LDs.

The HCV replication complex is compartmentalized by lipid bilayer membranes<sup>16-18</sup>. Therefore, HCV RNA in the complex is resistant to nuclease treatment in digitonin-permeabilized cells<sup>17</sup> (Supplementary Information, Fig. S4b-d). *In situ* hybridization analysis did not reveal a significant difference in the number of cells containing LD-associated HCV RNA before and after nuclease treatment (Fig. 2c), indicating that HCV RNA around LDs is part of the replication complex. An RNA synthesis assay showed that the purified LD fraction from JFH1<sup>E2FL</sup>-, but not JFH1<sup>dC3</sup>- or JFH1<sup>PP/AA</sup>-replicating cells, possessed HCV RNA synthesis activity, even though the expression levels of viral proteins and RNA-synthesizing activities in total cell lysates were similar (Fig. 2d). Moreover, the addition of Core<sup>W1</sup> rescued the localization of plus- and minus-strand



LETTERS




**Figure 3** Spatial distribution of Core and NS5A relative to the LD. (a, b) The localizations of Core, NS5A and ADRP around the lipid droplets (LDs) in JFH1<sup>E2FL</sup> replicon-bearing cells were analysed using immunofluorescence microscopy. Scale bars, 1  $\mu$ m. (c) Typical images of the localization of LDs, Core, NS5A and merged images are shown with the relative scale of each image. (d, e) Transmission electron micrographs of LDs in naive Huh-7 cells and JFH1<sup>E2FL</sup>-expressing cells. Arrows and arrowheads indicate LD-associated membranes and rough ER membranes, respectively. (f) Frequency of LDs with close appositions

of membrane cisternae. About 100 Huh-7 cells or JFH1<sup>E2FL</sup>-expressing cells, respectively, were chosen randomly. LDs with apposed membrane cisternae, as exemplified in panel e, were counted as positive. The LDs judged as positive were divided by the total number of LDs. (g–j) Immunoelectron micrographs of LDs labelled with antibodies against Core (g), NS5A (h, i) or both (j) are shown. Panel i is a higher magnification of area 1 in panel h. In panel j, Core and NS5A are labelled with 15 nm and 10 nm gold particles, respectively. Scale bars, 200 nm. All error bars are derived from s.d.

HCV RNA around LDs in JFH<sup>dC3</sup>-replicating cells (Fig. 2e and data not shown). Both plus- and minus-strand RNA associated with LDs were nuclease resistant (data not shown). These results demonstrate that Core recruits biologically active replication complexes to LDs.

The LD is surrounded by a phospholipid monolayer<sup>19</sup>, whereas HCV replication complexes are likely to be surrounded by lipid bilayer membranes<sup>16,17</sup>. Therefore, the replication complexes might not be directly


associated with the membranes of LDs. To characterize the colocalization of LDs, viral proteins and replication complexes more precisely, we analysed the localization of NS5A with high-resolution immunofluorescence microscopy. Core was completely colocalized with ADRP, residing on the surface of LDs<sup>20</sup> (Fig. 3a), thus indicating that Core also directly associates with the surface of LDs. More importantly, NS5A mainly localized around the Core-positive area, resulting in a doughnut-shaped signal with a diameter slightly



**Figure 4** LD associations of Core and NS proteins are necessary for the production of infectious HCV particles. (a) The culture medium from JFH1<sup>E2FL</sup>, JFH1<sup>ΔCS</sup>, or JFH1<sup>PP/AA</sup>-replicating cells was collected at the indicated time points and the titre of hepatitis C virus (HCV) RNA was measured by real-time RT-PCR (upper panel,  $n = 3$ ). The culture medium was added to naïve Huh7.5 cells and, 24 h after inoculation, and cells were labelled with anti-HCV antibodies (lower panels, red). (b) JFH1<sup>ΔCS</sup> replicon-bearing cells were transfected with pcDNA3 (EV), pcDNA3–Core<sup>WT</sup> (Core<sup>WT</sup>) or pcDNA3–Core<sup>PP/AA</sup> (Core<sup>PP/AA</sup>). The level of HCV RNA and the infectivity of the culture medium were examined as described above ( $n = 3$ ). (c) Subcellular localization of NS5A and Core in cells expressing JFH1<sup>AA99</sup>. The insets are high magnifications of the area of the corresponding panel. Scale bar, 2 μm. (d) Percentages of cells in which the signals for given HCV proteins, and plus- and minus-strand HCV RNA, overlapped with those for LDs ( $n > 200$ ). (e) Different amounts of JFH1<sup>E2FL</sup> (E2FL), JFH1<sup>AA99</sup> (99) or JFH1<sup>AA102</sup> (102) RNAs, respectively, were transfected into the same number of

Huh-7 cells. HCV RNA synthesis activity in purified LD fractions (LD) and whole-cell lysates (whole cell) was analysed (HCV RNA synthesis). 28S rRNA was used as a control. Western blot analysis of NS5A, NS5B and tubulin in cells is also shown. All the RNA samples in the top panel were run on the same gel. (f) Analysis of HCV released from cells expressing JFH1<sup>E2FL</sup>, JFH1<sup>AA99</sup> or JFH1<sup>AA102</sup>. HCV RNA titres (black bars) and amounts of Core (white bars) accumulated in the culture medium at 5 d after RNA transfection were measured (upper panel,  $n = 3$ ). Infectivity of the culture medium for naïve Huh-7.5 cells was analysed as described above (lower panels). (g) Concentrated culture medium from JFH1<sup>E2FL</sup> and JFH1<sup>AA99</sup>-replicating cells was fractionated using 20–50% sucrose density-gradient centrifugation at 100,000  $g$  for 16 h. For each fraction, the amounts of Core (black line), HCV RNA (blue line) and infectivity (represented by infected cell numbers in a well; red line) are plotted against the buoyant density ( $x$ -axis) ( $n = 3$ ). Uncropped images of gels are shown in Supplementary Information Fig. S6. All error bars are derived from s.d.

LETTERS



**Figure 5** Virus-assembly takes place around the LDs. (a) Immunoelectron microscopic detection of E2 and Core in JFH1<sup>E2FL</sup>-replicating cells. E2 and Core are labelled with 15 nm and 10 nm gold particles, respectively. (b) Western blot analysis of the lipid droplet (LD) fraction from JFH1<sup>E2FL</sup> and JFH1<sup>ΔC3</sup> replicon-bearing cells with anti-E2 and anti-ADRP antibodies. (c) Transmission electron micrographs of JFH1<sup>E2FL</sup>-replicating cells. Arrows indicate virus-like particles. (d) Immunoelectron micrographs of LDs labelled with antibodies against Core (10 nm) and E2 (15 nm) are shown. Arrows show Core in electron-dense granules. Scale bar: a and upper panel of c: 100 nm;

in d and lower panels of c: 50 nm. (e) A model for the production of infectious hepatitis C virus (HCV). Core mainly localizes on the monolayer membrane that surrounds the LD. HCV induces the apposition of the LD to the endoplasmic reticulum (ER)-derived bilayer membranes (LD-associated membrane). Core recruits NS proteins, as well as replication complexes, to the LD-associated membrane. NS proteins around the LD can then participate in infectious virus production. E2 also localizes around the LD. Through these associations, virion assembly proceeds in this local environment. Uncropped images of gels are shown in Supplementary Information Fig. S6.

larger than that of Core (Fig. 3b). The LD-proximal NS5A signal partially overlapped with the Core signal (Fig. 3b, c, grey). This concentric staining pattern was also observed with the other NS proteins (Supplementary Information, Fig. S5a), indicating that NS proteins associate with Core on the surface of LDs. Electron microscopic analysis only rarely revealed a close association of LDs with other organelles in naïve Huh-7 cells (Fig. 3d, f). However, in the case of JFH1<sup>E2FL</sup>-replicating cells, about 30% of the LDs were in close proximity to membrane cisternae (Fig. 3e, arrows; 3f), arguing for a HCV-induced membrane rearrangement around LDs. Core was mainly located on the periphery of LDs, and occasionally signals were

observed in more distal areas of the LDs (Fig. 3g, arrowheads and arrows, respectively). Although some NS5A signals were observed on the surface of the LD, the majority of NS5A signals were detected more distal of LDs (Fig. 3h, i). Furthermore, we often observed membrane cisternae as white lines in the same area as NS5A signals (Fig. 3i, arrows). When the same section was labelled with anti-Core and anti-NS5A antibodies, Core was detected on the surface of the LDs, whereas NS5A was mainly observed in the peripheral area of the LDs (Fig. 3j, arrowheads and arrows, respectively). In summary, these results show that Core recruits NS proteins, as well as HCV replication complexes, to the LD-associated membranes.

The above results prompted us to ask whether Core–LD colocalization is important for the production of infectious virus particles. JFH1<sup>E2FL</sup>-replicating cells released virions into the culture medium and these viruses were highly infectious for naïve Huh-7.5 cells<sup>11,21</sup>, although culture medium from JFH1<sup>PP/AA</sup>- or JFH1<sup>dC3</sup>-replicating cells did not contain significant levels of HCV RNA and infectious virus (Fig. 4a). However, following trans-complementation with Core<sup>wt</sup>, a high titre of HCV RNA and infectious virus could be rescued from JFH1<sup>dC3</sup>-replicating cells (Fig. 4b; and see Supplementary Information, Fig. S5b, c). In contrast, the production of infectious viruses was not rescued by trans-complementation with Core<sup>PP/AA</sup> (Fig. 4b). RNA-binding properties and oligomerization of Core<sup>wt</sup> and Core<sup>PP/AA</sup>, which are both necessary for virus assembly, were similar (Supplementary Information, Fig. S5d; ref. 22), arguing that the primary defect of this mutant in preventing infectious virus production is the inability to associate with LDs.

To investigate the contribution of NS proteins around LDs to infectious virus production, we used variants of NS5A, which were not recruited to LDs even in the presence of Core. We assumed that NS5A was crucial for recruiting other NS proteins to LDs, because the level of NS5A recruited to LDs via Core was higher than the levels of the other recruited NS proteins (Fig. 1c, JFH1<sup>E2FL</sup>). Using alanine-scanning mutagenesis within the NS5A coding region of JFH1<sup>E2FL</sup>, we generated two mutants, JFH1<sup>AAA99</sup> and JFH1<sup>AAA102</sup>, in which the amino-acid sequence APK (aa 99–101 of NS5A) or PPT (aa 102–104 of NS5A) was replaced by AAA (Supplementary Information, Fig. S1). In JFH1<sup>AAA99</sup>- and JFH1<sup>AAA102</sup>-replicating cells, NS5A was rarely detected around LDs, whereas Core was still localized to LDs (Fig. 4c, d). Importantly, these mutations impaired not only the NS5A association with LDs, but also the recruitment of other NS proteins and viral RNAs to LDs (Fig. 4d). These results indicate that NS5A is a key protein that recruits replication complexes to LDs. Importantly, HCV RNA synthesis activity in the LD fractions from these mutant JFH1-replicating cells was also severely impaired (Fig. 4e), corroborating the lack of association of HCV replication complexes with LDs.

To investigate the infectious virus production of these NS5A mutants, we prepared cells expressing similar levels of HCV proteins and RNA by adjusting the amount of transfected HCV RNA (Fig. 4e). This was necessary, because replication activities of these mutants were lower compared with JFH1<sup>E2FL</sup>. Under these conditions, the amounts of Core and HCV RNA that were released into the culture medium from cells transfected with the mutants were comparable to JFH1<sup>E2FL</sup> (Fig. 4f, upper graph). However, infectivity titres of the mutants were severely reduced (Fig. 4f, lower panels). In sucrose density-gradient centrifugation of culture medium from JFH1<sup>E2FL</sup>-bearing cells, two types of HCV particles were detected: low-density particles (about 1.12 g ml<sup>-1</sup>) with high infectivity (Fig. 4g, green area of JFH1<sup>E2FL</sup>), and high-density particles (about 1.15 g ml<sup>-1</sup>) without infectivity (yellow area). This result indicates that only a minor portion of released HCV particles is infectious, whereas the majority of released particles lack infectivity. In contrast, cells bearing the JFH1<sup>AAA99</sup> mutant almost exclusively released non-infectious particles of around 1.15 g ml<sup>-1</sup>, whereas infectious particles were barely detectable (Fig. 4g, JFH1<sup>AAA99</sup>). Taken together, these results provide convincing evidence that the association of NS proteins and replication complexes around LDs is critical for producing infectious viruses, whereas production of non-infectious viruses seems to follow a different pathway.

The results described so far imply that some step(s) of HCV assembly take place around LDs. To explore this possibility, we analysed the distribution of the major envelope protein E2 around the LD. Electron microscopic analysis revealed that, in about 90% of JFH1<sup>E2FL</sup>-replicating cells, E2 was localized in the peripheral area of the LDs (Fig. 5a, large grains). This labelling pattern was similar to the one observed for NS5A (Fig. 3j), indicating that E2 also localizes on the LD-associated membranes. Western blot analysis of the LD fraction supported this conclusion, because the LD fraction that was purified from JFH1<sup>E2FL</sup>-replicating cells, but not from JFH1<sup>dC3</sup>-replicating cells, contained E2 (Fig. 5b). Furthermore, spherical virus-like particles with an average diameter of about 50 nm were observed around LDs in JFH1<sup>E2FL</sup>-replicating cells (Fig. 5c, upper panel). These particles were never observed in naïve Huh-7 cells. A more refined analysis indicates that these particles are closely associated with membranes in close proximity to LDs (Fig. 5c, lower panels, arrows). Finally, these particles around the LDs reacted with Core- and E2-specific antibodies, arguing that the particles represent true HCV virions (Fig. 5d). These results suggest that infectious HCV particles are generated from the LD-associated membranous environment.

In this study, we have demonstrated that Core recruits NS proteins, HCV RNAs and the replication complex to LD-associated membranes. Mutations of Core and NS5A (Fig. 4), which failed to associate with LDs, impaired the production of infectious virus. We note that the mutant Core retains the ability to interact with RNA (Supplementary Information, Fig. S5b) and to assemble into nucleocapsid<sup>22</sup>. Similarly, the NS5A mutant still supports viral genome replication and the formation of capsids or virus-like particles, arguing that the introduced mutations in Core and NS5A do not affect overall protein folding, stability or function (Fig. 4). Taken together, the data show that the association of HCV proteins with LDs is important for the production of infectious viral particles (Fig. 5e).

Our results also indicate that NS proteins around the LDs participate in the assembly of infectious virus particles. In one scenario, NS proteins may indirectly contribute to the different steps of virus production — for example, by establishing the microenvironment around the LDs that is required for infectious virus production. Alternatively, NS proteins around the LDs may directly participate in virus production — for example, as components of the replication complex that provide the RNA genome to the assembling nucleocapsid.

In support of the role of LDs in virus formation, we observed that colocalization of HCV protein with LDs was low in cases of the chimera Jc1, supporting up to 1,000-fold higher infectivity titres compared with JFH1 (ref. 13). In a Jc1-infected cell, only about 20% of LDs demonstrated detectable colocalization with Core, but this value increased to 80% in the case of a Jc1 mutant lacking most of the envelope glycoprotein genes and thus being unable to produce infectious virus particles (data not shown). This inverse correlation between the efficiency of virus production and Core protein accumulation on LDs indicates that rapid assembly and virus release results in the rapid liberation of HCV proteins from the LDs.

Steatosis and abnormal lipid metabolism caused by chronic HCV infection may be linked to enhanced LD formation<sup>14</sup>. In fact, the overproduction of LDs is induced by Core (Supplementary Information, Fig. S3) and HCV also induces membrane rearrangements around LDs (Fig. 3d–f). Our findings suggest that excessive Core-dependent formation of LDs

## LETTERS

and membrane rearrangements are required to supply the necessary microenvironment for virus production. NS proteins and HCV RNA seem to be translocated from the ER to the LD-associated membranes. Interestingly, the LD-associated membranes were occasionally found in continuity with ribosome-studded rough ER (Fig. 3e, arrowheads). Thus, at least parts of the LD-associated membranes are likely to be derived from ER membranes. ER marker proteins, however, were not detected in the LD fraction, suggesting that the LD-associated membrane is characteristically distinct from that of ER membranes.

To our knowledge, this is the first report showing that LDs are required for the formation of infectious virus particles. The fact that capsid protein of the hepatitis G virus also localizes to LDs<sup>15</sup> indicates that LDs might be important for the production of other viruses as well. Our findings demonstrate a novel function of LDs, provide an important step towards elucidating the mechanism of HCV virion production and open new avenues for novel antiviral intervention. □

## METHODS

**Antibodies.** The antibodies used for immunoblotting and immunolabelling were specific for Core (#32-1 and RR8); E2 (AP-33 (ref. 23); 3/11, CBH5 and Flag M2 (Sigma-Aldrich, St Louis, MO); NS3 (R212)<sup>17</sup>; NS4A and 4B (PR12); NS5A (NS5ACL1); NS5B (NS5B-6 and JFH1-1)<sup>24</sup>; ADRP (Progen Biotechnik, Heidelberg, Germany); tubulin (Oncogene Research Products, MA, USA); Grp78 (StressGen, Victoria, Canada); PDI (StressGen); and Calnexin-NT (StressGen). Antibodies specific for Core (#32-1 and RR8), NS3 (R212) and NS4AB (PR12) were gifts from Dr Kohara (The Tokyo Metropolitan Institute of Medical Science, Japan). Anti-E2 antibody (AP-33) was provided by Dr Patel (MRC Virology Unit, UK). Anti-NS5B (NS5B-6) antibody was kindly provided by Dr Fukuya (Osaka University, Japan). Rabbit polyclonal antibodies specific for NS5A were raised against a bacterially expressed GST-NS5A (1–406 aa) fusion protein. In the case of the HCV chimeras Con1/C3 and H77/C3, immunofluorescence analyses were performed by using the following antibodies: Core (C7/50)<sup>5</sup>, a JFH1 NS3-specific rabbit polyclonal antiserum; NS4B (#86)<sup>25</sup>; and NS5A (Austral Biologicals, San Ramon, CA).

**Indirect immunofluorescence analysis.** Indirect immunofluorescence analysis was performed essentially as described previously<sup>17</sup>, with slight modifications. Cells transfected with JFH1 RNA were seeded onto a collagen-coated Labtech II 8-well chamber (Nunc, NY, USA). The coating with collagen was performed using rat-tail collagen type I (BD Bioscience, Palo Alto, CA) according to manufacturer's instructions. Three days after seeding, the cells were washed twice with phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na<sub>2</sub>HPO<sub>4</sub> and 1.4 mM KH<sub>2</sub>PO<sub>4</sub>) and fixed with fixation solution (4% paraformaldehyde and 0.15 M sodium cacodylate at pH 7.4) for 15 min at room temperature. After washing with PBS, the cells were permeabilized with 0.05% Triton X-100 in PBS for 15 min at room temperature. For the precise localization of the proteins, the cells were permeabilized with 50 µg ml<sup>-1</sup> of digitonin in PBS for 5 min at room temperature<sup>26</sup>. After incubating the cells with blocking solution (10% fetal bovine serum and 5% bovine serum albumin (BSA) in PBS) for 30 min, the cells were incubated with the primary antibodies. The fluorescent secondary antibodies were Alexa 568- or Alexa 647-conjugated anti-mouse or anti-rabbit IgG antibodies (Invitrogen, Carlsbad, CA). Nuclei were labelled with 4',6-diamidino-2-phenylindole (DAPI). LDs were visualized with BODIPY 493/503 (Invitrogen). Analyses of JFH1 were performed on a Leica SP2 confocal microscope (Leica, Heidelberg, Germany). Analysis of the Con1/C3 and the H77/C3 chimeras was performed in the same way, except that imaging was performed on a Nikon C1 confocal microscope (Nikon, Tokyo, Japan).

**Electron microscopy.** For conventional electron microscopy, cells cultured in plastic Petri dishes were processed *in situ*. The cells were fixed in 2.5% glutaraldehyde and 0.1 M sodium phosphate (pH 7.4), and then in OsO<sub>4</sub> and 0.1 M sodium phosphate (pH 7.4). The cells were then dehydrated in a graded ethanol series and embedded in an epoxy resin. Ultrathin sections were cut perpendicular to the base of the dish. For immuno-electron microscopy, cells were detached

from the dish with a cell scraper after fixation in 4% paraformaldehyde, 0.1% glutaraldehyde and 0.1 M sodium phosphate (pH 7.4) for 24 h, and washed in 0.1 M lysine, 0.1 M sodium phosphate (pH 7.4) and 0.15 M sodium chloride. After dehydrating the cells in a graded series of cold ethanol, they were embedded in Lowicryl K4M at -20 °C. Ultrathin sections were labelled with primary antibodies and colloidal gold particles (15 nm) conjugated to anti-mouse IgG or anti-rabbit IgG antibodies. For double labelling, colloidal gold particles with different diameters (10 nm and 15 nm) conjugated to anti-mouse IgG or anti-rabbit antibodies were used. Samples were observed after staining with uranyl acetate and lead citrate with a JEM 1010 electron microscope at the accelerating voltage of 80 kV. Anti-Core (#32-1 and RR8), anti-NS5A (NS5ACL1) and anti-E2 (Flag M2) antibodies were used.

**Preparation of the lipid droplets.** Cells at a confluency of ~80% on a dish with a diameter of 14 cm were scraped in PBS. The cells were pelleted by centrifugation at 1,500 rpm. The pellet was resuspended in 500 µl of hypotonic buffer (50 mM HEPES, 1 mM EDTA and 2 mM MgCl<sub>2</sub> at pH 7.4) supplemented with protease inhibitors (Roche Diagnostics, Basel, Switzerland) and was incubated for 10 min at 4 °C. The suspension was homogenized with 30 strokes of a glass Dounce homogenizer using a tight-fitting pestle. Then, 50 µl of 10× sucrose buffer (0.2 M HEPES, 1.2 M KoAc, 40 mM Mg(OAc)<sub>2</sub> and 50 mM DTT at pH 7.4) was added to the homogenate. The nuclei were removed by centrifugation at 2,000 rpm for 10 min at 4 °C. The supernatant was collected and centrifuged at 16,000 g for 10 min at 4 °C. The supernatant (S16) was mixed with an equal volume of 1.04 M sucrose in isotonic buffer (50 mM HEPES, 100 mM KCl, 2 mM MgCl<sub>2</sub> and protease inhibitors). The solution was set at the bottom of 2.2-ml ultracentrifuge tube (Hitachi Koki, Tokyo, Japan). One milliliter of isotonic buffer was loaded onto the sucrose mixture. The tube was centrifuged at 100,000 g in an S55S rotor (Hitachi Koki) for 30 min at 4 °C. After the centrifugation, the LD fraction on the top of the gradient solution was recovered in isotonic buffer. The suspension was mixed with 1.04 M sucrose and centrifuged again at 100,000 g, as described above, to eliminate possible contamination with other organelles. The collected LD fraction was used for western blotting or the HCV RNA synthesis assay.

**HCV RNA synthesis assay.** An assay of HCV RNA synthesis using digitonin-permeabilized cells was performed as described previously<sup>17</sup>. For RNA synthesis assays using the LD fraction, the LD fraction collected by sucrose-gradient sedimentation was suspended in buffer B, which contained 2 mM manganese (II) chloride, 1 mg ml<sup>-1</sup> acetylated BSA (Nacalai Tesque, Kyoto, Japan), 5 mM phosphocreatine (Sigma), 20 units/ml creatine phosphokinase (Sigma), 50 µg ml<sup>-1</sup> actinomycin D, 500 µM ATP, 500 µM CTP, 500 µM GTP (Roche Diagnostics) and 1.85 MBq of [α-<sup>32</sup>P] UTP (GE Healthcare, Little Chalfont, UK), and incubated at 27 °C for 4 h. The reaction products were analysed by gel electrophoresis followed by autoradiography.

*Note: Supplementary Information is available on the Nature Cell Biology website.*

## ACKNOWLEDGEMENTS

We thank T. Fujimoto and Y. Ohsaki at Nagoya University for helpful discussions and technical assistance. Y.M. is a recipient of a JSPS fellowship. K.S. is supported by Grants-in-Aid for cancer research and for the second-term comprehensive 10-year strategy for cancer control from the Ministry of Health, Labour and Welfare, as well as by a Grant-in-Aid for Scientific Research on Priority Areas "Integrative Research Toward the Conquest of Cancer" from the Ministry of Education, Culture, Sports, Science and Technology of Japan. T.W. is also supported, in part, by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science; and by the Research on Health Sciences Focusing on Drug Innovation from the Japan Health Sciences Foundation. R.B. is supported by the Sonderforschungsbereich 638 (Teilprojekt A5) and the Deutsche Forschungsgemeinschaft (BA1505/2-1). M.Z. and R.B. thank the Nikon Imaging Center at the University of Heidelberg for providing access to their confocal fluorescence microscopes and Ulrike Engel for the excellent support.

## AUTHOR CONTRIBUTIONS

Y.M. and K.S. planned experiments and analyses. Y.M. was responsible for experiments for Figs 1, 2, 3a–c, 4a–e and 5b. K.A., N.U., electron microscopy; T.H., Fig. 1e; M.Z., R.B., Fig. S2e; and K.S. and K.W., Fig. 4f–g. T.W. provided JFH1 strain. Y.M. and K.S. wrote the manuscript. All authors discussed the results and commented on the manuscript.